DD248362A5 - PROCESS FOR THE PREPARATION OF NEW PYRIDAZINONE - Google Patents
PROCESS FOR THE PREPARATION OF NEW PYRIDAZINONE Download PDFInfo
- Publication number
- DD248362A5 DD248362A5 DD86288285A DD28828586A DD248362A5 DD 248362 A5 DD248362 A5 DD 248362A5 DD 86288285 A DD86288285 A DD 86288285A DD 28828586 A DD28828586 A DD 28828586A DD 248362 A5 DD248362 A5 DD 248362A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- group
- methyl
- pyridazinone
- dihydro
- atom
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 19
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 43
- 239000002253 acid Substances 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 150000007524 organic acids Chemical class 0.000 claims abstract description 6
- 235000005985 organic acids Nutrition 0.000 claims abstract description 6
- 150000007522 mineralic acids Chemical class 0.000 claims abstract description 4
- -1 morpholino, thiomorpholino, 1-oxidothiomorpholino Chemical group 0.000 claims description 114
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 19
- 150000001721 carbon Chemical group 0.000 claims description 18
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 18
- 229960000583 acetic acid Drugs 0.000 claims description 16
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 125000004434 sulfur atom Chemical group 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 239000001301 oxygen Substances 0.000 claims description 15
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 14
- 239000012362 glacial acetic acid Substances 0.000 claims description 14
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 14
- 229920000137 polyphosphoric acid Polymers 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 238000005984 hydrogenation reaction Methods 0.000 claims description 7
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 239000011541 reaction mixture Substances 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 6
- 229940093915 gynecological organic acid Drugs 0.000 claims description 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 4
- 230000010933 acylation Effects 0.000 claims description 4
- 238000005917 acylation reaction Methods 0.000 claims description 4
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 238000005695 dehalogenation reaction Methods 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical group 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000005277 alkyl imino group Chemical group 0.000 claims description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 2
- 230000000269 nucleophilic effect Effects 0.000 claims description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 150000003217 pyrazoles Chemical class 0.000 claims description 2
- 150000003222 pyridines Chemical class 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 abstract description 5
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 abstract description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract description 2
- 238000011321 prophylaxis Methods 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 abstract description 2
- 206010014513 Embolism arterial Diseases 0.000 abstract 1
- 238000002844 melting Methods 0.000 description 73
- 230000008018 melting Effects 0.000 description 73
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 16
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- WEJXNMVJEXBSQF-UHFFFAOYSA-N 4-methyl-3-(2-methylsulfanyl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1=C2OC(SC)=NC2=CC=C1C1=NNC(=O)CC1C WEJXNMVJEXBSQF-UHFFFAOYSA-N 0.000 description 10
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 10
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- XHFMZTGMZOPLPG-UHFFFAOYSA-N 3-(2-methylsulfanyl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1=C2OC(SC)=NC2=CC=C1C1=NNC(=O)CC1 XHFMZTGMZOPLPG-UHFFFAOYSA-N 0.000 description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- ORSUMIZRRGPJBR-UHFFFAOYSA-N 4,5-dihydro-1h-pyridazin-6-one Chemical compound O=C1CCC=NN1 ORSUMIZRRGPJBR-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- UHYVTWWKARNAPE-UHFFFAOYSA-N 4-methyl-3-(2-methylsulfanyl-1,3-benzoxazol-5-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound C=1C=C2OC(SC)=NC2=CC=1C1=NNC(=O)CC1C UHYVTWWKARNAPE-UHFFFAOYSA-N 0.000 description 5
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N 4-methylimidazole Chemical compound CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 3
- JVDKSRXXEBKANQ-UHFFFAOYSA-N 3-(2-imidazol-1-yl-3h-benzimidazol-5-yl)-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(N2)N3C=NC=C3)C2=C1 JVDKSRXXEBKANQ-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 230000003177 cardiotonic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 2
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 2
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- OQFWEYYPGHWIHY-UHFFFAOYSA-N 3-(2-methylsulfanyl-1,3-benzoxazol-5-yl)-4-propyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CCCC1CC(=O)NN=C1C1=CC=C(OC(SC)=N2)C2=C1 OQFWEYYPGHWIHY-UHFFFAOYSA-N 0.000 description 2
- DPWPMUSGLLXNQL-UHFFFAOYSA-N 3-[2-(2,6-dichloropyridin-3-yl)-1,3-benzoxazol-6-yl]-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3C(=NC(Cl)=CC=3)Cl)C2=C1 DPWPMUSGLLXNQL-UHFFFAOYSA-N 0.000 description 2
- KOYZLXFXQWUVFN-UHFFFAOYSA-N 3-[2-(2,6-dichloropyridin-4-yl)-3h-benzimidazol-5-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound ClC1=NC(Cl)=CC(C=2NC3=CC(=CC=C3N=2)C=2CCC(=O)NN=2)=C1 KOYZLXFXQWUVFN-UHFFFAOYSA-N 0.000 description 2
- RMLXSVHNVQIFTQ-UHFFFAOYSA-N 4-methyl-3-(2-pyrrolidin-1-yl-3h-benzimidazol-5-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(N2)N3CCCC3)C2=C1 RMLXSVHNVQIFTQ-UHFFFAOYSA-N 0.000 description 2
- KMQLIDDEQAJAGJ-UHFFFAOYSA-N 4-oxo-4-phenylbutyric acid Chemical class OC(=O)CCC(=O)C1=CC=CC=C1 KMQLIDDEQAJAGJ-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- OQAGVSWESNCJJT-UHFFFAOYSA-N Methyl 3-methylbutanoate Chemical compound COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- LNOQURRKNJKKBU-UHFFFAOYSA-N ethyl piperazine-1-carboxylate Chemical compound CCOC(=O)N1CCNCC1 LNOQURRKNJKKBU-UHFFFAOYSA-N 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- DCDYNCXCJUOYCO-UHFFFAOYSA-N methyl 4-(2-chloro-3H-benzimidazol-5-yl)-3-methyl-4-oxobutanoate Chemical compound COC(CC(C(=O)C1=CC2=C(N=C(N2)Cl)C=C1)C)=O DCDYNCXCJUOYCO-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000009090 positive inotropic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- 125000005505 thiomorpholino group Chemical group 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- XXBHAKNXIAGMOG-UHFFFAOYSA-N 2,6-dichloro-n-[2-hydroxy-4-(4-methyl-6-oxo-4,5-dihydro-1h-pyridazin-3-yl)phenyl]pyridine-3-carboxamide Chemical compound CC1CC(=O)NN=C1C(C=C1O)=CC=C1NC(=O)C1=CC=C(Cl)N=C1Cl XXBHAKNXIAGMOG-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- RPSKGTHUYYLURN-UHFFFAOYSA-N 3-(2-chloro-3h-benzimidazol-5-yl)-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(Cl)N2)C2=C1 RPSKGTHUYYLURN-UHFFFAOYSA-N 0.000 description 1
- JUTQWCNIWCTVPD-UHFFFAOYSA-N 3-(2-imidazol-1-yl-1,3-benzoxazol-5-yl)-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(OC(=N2)N3C=NC=C3)C2=C1 JUTQWCNIWCTVPD-UHFFFAOYSA-N 0.000 description 1
- WLOFNCMLWPQUTP-UHFFFAOYSA-N 3-(2-imidazol-1-yl-1,3-benzoxazol-5-yl)-4-propyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CCCC1CC(=O)NN=C1C1=CC=C(OC(=N2)N3C=NC=C3)C2=C1 WLOFNCMLWPQUTP-UHFFFAOYSA-N 0.000 description 1
- LYERDLOJXZZCLH-UHFFFAOYSA-N 3-(2-imidazol-1-yl-1,3-benzoxazol-6-yl)-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)N3C=NC=C3)C2=C1 LYERDLOJXZZCLH-UHFFFAOYSA-N 0.000 description 1
- VCTMAOPXSADEHZ-UHFFFAOYSA-N 3-(2-methylsulfanyl-1,3-benzoxazol-5-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound C=1C=C2OC(SC)=NC2=CC=1C1=NNC(=O)CC1 VCTMAOPXSADEHZ-UHFFFAOYSA-N 0.000 description 1
- DHLNWWQZJFIHTF-UHFFFAOYSA-N 3-(2-piperazin-1-yl-1,3-benzoxazol-5-yl)-4-propyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CCCC1CC(=O)NN=C1C1=CC=C(OC(=N2)N3CCNCC3)C2=C1 DHLNWWQZJFIHTF-UHFFFAOYSA-N 0.000 description 1
- XOJQFYDKGRNAGE-UHFFFAOYSA-N 3-(2-piperazin-1-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=C3OC(=NC3=CC=2)N2CCNCC2)=N1 XOJQFYDKGRNAGE-UHFFFAOYSA-N 0.000 description 1
- JJDHQIXXASOFEU-UHFFFAOYSA-N 3-(2-pyridin-2-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=C3OC(=NC3=CC=2)C=2N=CC=CC=2)=N1 JJDHQIXXASOFEU-UHFFFAOYSA-N 0.000 description 1
- NUENUAKRFGZENA-UHFFFAOYSA-N 3-(2-pyrrolidin-1-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=C3OC(=NC3=CC=2)N2CCCC2)=N1 NUENUAKRFGZENA-UHFFFAOYSA-N 0.000 description 1
- CYEHHNQDDVAEPC-UHFFFAOYSA-N 3-(2-thiophen-2-yl-3h-benzimidazol-5-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=C3NC(=NC3=CC=2)C=2SC=CC=2)=N1 CYEHHNQDDVAEPC-UHFFFAOYSA-N 0.000 description 1
- BXGRTKMGXMFZDD-UHFFFAOYSA-N 3-(2-thiophen-3-yl-1,3-benzoxazol-5-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=C3N=C(OC3=CC=2)C2=CSC=C2)=N1 BXGRTKMGXMFZDD-UHFFFAOYSA-N 0.000 description 1
- VJRBSHZAWWZIKM-UHFFFAOYSA-N 3-(2-thiophen-3-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=C3OC(=NC3=CC=2)C2=CSC=C2)=N1 VJRBSHZAWWZIKM-UHFFFAOYSA-N 0.000 description 1
- FLMNGRPCHGSXTL-UHFFFAOYSA-N 3-(2-thiophen-3-yl-3h-benzimidazol-5-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=C3NC(=NC3=CC=2)C2=CSC=C2)=N1 FLMNGRPCHGSXTL-UHFFFAOYSA-N 0.000 description 1
- JKRCTHRZIZKECH-UHFFFAOYSA-N 3-(4-amino-3-hydroxyphenyl)-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N)C(O)=C1 JKRCTHRZIZKECH-UHFFFAOYSA-N 0.000 description 1
- PYZZOOGXTXLTKS-UHFFFAOYSA-N 3-[2-(2,6-dichloropyridin-4-yl)-3h-benzimidazol-5-yl]-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(N2)C=3C=C(Cl)N=C(Cl)C=3)C2=C1 PYZZOOGXTXLTKS-UHFFFAOYSA-N 0.000 description 1
- PFDNDFPHKWFHJL-UHFFFAOYSA-N 3-[2-(2-chloro-6-morpholin-4-ylpyridin-4-yl)-3h-benzimidazol-5-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound N=1C(Cl)=CC(C=2NC3=CC(=CC=C3N=2)C=2CCC(=O)NN=2)=CC=1N1CCOCC1 PFDNDFPHKWFHJL-UHFFFAOYSA-N 0.000 description 1
- CMQGUDFDPOBKGI-UHFFFAOYSA-N 3-[2-(2-methylimidazol-1-yl)-1,3-benzoxazol-5-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1=NC=CN1C1=NC2=CC(C=3CCC(=O)NN=3)=CC=C2O1 CMQGUDFDPOBKGI-UHFFFAOYSA-N 0.000 description 1
- XRNJUIUBFHXNHA-UHFFFAOYSA-N 3-[2-(4-acetylpiperazin-1-yl)-3h-benzimidazol-5-yl]-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(N2)N3CCN(CC3)C(C)=O)C2=C1 XRNJUIUBFHXNHA-UHFFFAOYSA-N 0.000 description 1
- UULZACIDJNFNCW-UHFFFAOYSA-N 3-[2-(4-methyl-1,3-oxazol-5-yl)-1,3-benzoxazol-5-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1=COC(C=2OC3=CC=C(C=C3N=2)C=2CCC(=O)NN=2)=C1C UULZACIDJNFNCW-UHFFFAOYSA-N 0.000 description 1
- LESAKQVAMKXSHZ-UHFFFAOYSA-N 3-[2-(4-methylimidazol-1-yl)-1,3-benzoxazol-6-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1=NC(C)=CN1C1=NC2=CC=C(C=3CCC(=O)NN=3)C=C2O1 LESAKQVAMKXSHZ-UHFFFAOYSA-N 0.000 description 1
- ONQJAHPGSXJCAC-UHFFFAOYSA-N 3-[2-(4-methylpiperazin-1-yl)-1,3-benzoxazol-6-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1CN(C)CCN1C1=NC2=CC=C(C=3CCC(=O)NN=3)C=C2O1 ONQJAHPGSXJCAC-UHFFFAOYSA-N 0.000 description 1
- ZAUCTQWJCVGYJO-UHFFFAOYSA-N 3-[2-(6-aminopyridin-3-yl)-1,3-benzoxazol-6-yl]-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3C=NC(N)=CC=3)C2=C1 ZAUCTQWJCVGYJO-UHFFFAOYSA-N 0.000 description 1
- GMUOHBUWIXJMLD-UHFFFAOYSA-N 3-[2-(azepan-1-yl)-3h-benzimidazol-5-yl]-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(N2)N3CCCCCC3)C2=C1 GMUOHBUWIXJMLD-UHFFFAOYSA-N 0.000 description 1
- OUSJEKODFGKNMR-UHFFFAOYSA-N 3-[2-(furan-2-yl)-1,3-benzothiazol-5-yl]-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(SC(=N2)C=3OC=CC=3)C2=C1 OUSJEKODFGKNMR-UHFFFAOYSA-N 0.000 description 1
- ZUTPXCFIWKYBJH-UHFFFAOYSA-N 3-[2-(furan-2-yl)-1,3-benzoxazol-5-yl]-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(OC(=N2)C=3OC=CC=3)C2=C1 ZUTPXCFIWKYBJH-UHFFFAOYSA-N 0.000 description 1
- KXAXSCKODDCDEI-UHFFFAOYSA-N 3-[2-(furan-2-yl)-1,3-benzoxazol-6-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=C3OC(=NC3=CC=2)C=2OC=CC=2)=N1 KXAXSCKODDCDEI-UHFFFAOYSA-N 0.000 description 1
- ONMHFWXBCYQUHR-UHFFFAOYSA-N 3-[2-(furan-2-yl)-1,3-benzoxazol-6-yl]-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3OC=CC=3)C2=C1 ONMHFWXBCYQUHR-UHFFFAOYSA-N 0.000 description 1
- CFSCXFNBEXFTJO-UHFFFAOYSA-N 3-[2-(furan-2-yl)-3h-benzimidazol-5-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=C3NC(=NC3=CC=2)C=2OC=CC=2)=N1 CFSCXFNBEXFTJO-UHFFFAOYSA-N 0.000 description 1
- SKAGJVNSBFSHCW-UHFFFAOYSA-N 3-[2-(furan-2-yl)-3h-benzimidazol-5-yl]-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(N2)C=3OC=CC=3)C2=C1 SKAGJVNSBFSHCW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- JQLMESSMJOVURI-UHFFFAOYSA-N 4-methyl-3-(2-piperazin-1-yl-1,3-benzoxazol-5-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(OC(=N2)N3CCNCC3)C2=C1 JQLMESSMJOVURI-UHFFFAOYSA-N 0.000 description 1
- RZFBQWBFPTUWJO-UHFFFAOYSA-N 4-methyl-3-(2-piperazin-1-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)N3CCNCC3)C2=C1 RZFBQWBFPTUWJO-UHFFFAOYSA-N 0.000 description 1
- PEYREFTTXSMFJA-UHFFFAOYSA-N 4-methyl-3-(2-pyrazin-2-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3N=CC=NC=3)C2=C1 PEYREFTTXSMFJA-UHFFFAOYSA-N 0.000 description 1
- MZNOWYRMUHWDHN-UHFFFAOYSA-N 4-methyl-3-(2-pyrazol-1-yl-3h-benzimidazol-5-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(N2)N3N=CC=C3)C2=C1 MZNOWYRMUHWDHN-UHFFFAOYSA-N 0.000 description 1
- WBLUKZKWOCUDNJ-UHFFFAOYSA-N 4-methyl-3-(2-pyridin-2-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3N=CC=CC=3)C2=C1 WBLUKZKWOCUDNJ-UHFFFAOYSA-N 0.000 description 1
- GWPJBMULVFLBDI-UHFFFAOYSA-N 4-methyl-3-(2-pyridin-3-yl-1,3-benzoxazol-5-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(OC(=N2)C=3C=NC=CC=3)C2=C1 GWPJBMULVFLBDI-UHFFFAOYSA-N 0.000 description 1
- HZPCPJCKBVVBPN-UHFFFAOYSA-N 4-methyl-3-(2-pyridin-3-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3C=NC=CC=3)C2=C1 HZPCPJCKBVVBPN-UHFFFAOYSA-N 0.000 description 1
- KZRDJRHPXSWGPR-UHFFFAOYSA-N 4-methyl-3-(2-pyridin-4-yl-1,3-benzoxazol-5-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(OC(=N2)C=3C=CN=CC=3)C2=C1 KZRDJRHPXSWGPR-UHFFFAOYSA-N 0.000 description 1
- GVFKMZWXGLRDSL-UHFFFAOYSA-N 4-methyl-3-(2-pyridin-4-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3C=CN=CC=3)C2=C1 GVFKMZWXGLRDSL-UHFFFAOYSA-N 0.000 description 1
- GWVGQEHDTMTWGA-UHFFFAOYSA-N 4-methyl-3-(2-pyrimidin-5-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3C=NC=NC=3)C2=C1 GWVGQEHDTMTWGA-UHFFFAOYSA-N 0.000 description 1
- WDMXXUCBBQXOBP-UHFFFAOYSA-N 4-methyl-3-(2-pyrrolidin-1-yl-1,3-benzoxazol-5-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(OC(=N2)N3CCCC3)C2=C1 WDMXXUCBBQXOBP-UHFFFAOYSA-N 0.000 description 1
- OJQZGKVBHOCFJU-UHFFFAOYSA-N 4-methyl-3-(2-pyrrolidin-1-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)N3CCCC3)C2=C1 OJQZGKVBHOCFJU-UHFFFAOYSA-N 0.000 description 1
- FNVMCSUDRWDONS-UHFFFAOYSA-N 4-methyl-3-(2-pyrrolidin-1-yl-3h-benzimidazol-5-yl)-1h-pyridazin-6-one Chemical compound CC1=CC(=O)NN=C1C1=CC=C(N=C(N2)N3CCCC3)C2=C1 FNVMCSUDRWDONS-UHFFFAOYSA-N 0.000 description 1
- OCDVTFLVYWNCJA-UHFFFAOYSA-N 4-methyl-3-(2-thiophen-2-yl-1,3-benzothiazol-5-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(SC(=N2)C=3SC=CC=3)C2=C1 OCDVTFLVYWNCJA-UHFFFAOYSA-N 0.000 description 1
- YPZOGCYARKOOPS-UHFFFAOYSA-N 4-methyl-3-(2-thiophen-2-yl-1,3-benzoxazol-5-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(OC(=N2)C=3SC=CC=3)C2=C1 YPZOGCYARKOOPS-UHFFFAOYSA-N 0.000 description 1
- UZUZMMPWZNVNSQ-UHFFFAOYSA-N 4-methyl-3-(2-thiophen-2-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3SC=CC=3)C2=C1 UZUZMMPWZNVNSQ-UHFFFAOYSA-N 0.000 description 1
- QFJXFMDTNXFNGV-UHFFFAOYSA-N 4-methyl-3-(2-thiophen-3-yl-1,3-benzoxazol-5-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(OC(=N2)C3=CSC=C3)C2=C1 QFJXFMDTNXFNGV-UHFFFAOYSA-N 0.000 description 1
- AWBKPTGTOZQNBX-UHFFFAOYSA-N 4-methyl-3-(2-thiophen-3-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C3=CSC=C3)C2=C1 AWBKPTGTOZQNBX-UHFFFAOYSA-N 0.000 description 1
- HHLXZPHWLFLYJE-UHFFFAOYSA-N 4-methyl-3-(2-thiophen-3-yl-3h-benzimidazol-5-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(N2)C3=CSC=C3)C2=C1 HHLXZPHWLFLYJE-UHFFFAOYSA-N 0.000 description 1
- FJGKCOIJXAFKEK-UHFFFAOYSA-N 4-methyl-3-[2-(1H-pyrrol-2-yl)-3H-benzimidazol-5-yl]-4,5-dihydro-1H-pyridazin-6-one Chemical compound CC1CC(NN=C1C1=CC2=C(N=C(N2)C=2NC=CC=2)C=C1)=O FJGKCOIJXAFKEK-UHFFFAOYSA-N 0.000 description 1
- ZOEAXLFGDMFIBL-UHFFFAOYSA-N 4-methyl-3-[2-(2-methylimidazol-1-yl)-1,3-benzoxazol-5-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(OC(=N2)N3C(=NC=C3)C)C2=C1 ZOEAXLFGDMFIBL-UHFFFAOYSA-N 0.000 description 1
- PEWKJDRWEYVZKM-UHFFFAOYSA-N 4-methyl-3-[2-(2-oxoimidazolidin-1-yl)-3h-benzimidazol-5-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(N2)N3C(NCC3)=O)C2=C1 PEWKJDRWEYVZKM-UHFFFAOYSA-N 0.000 description 1
- JHSPFPIXWVTTAA-UHFFFAOYSA-N 4-methyl-3-[2-(3-methylpyrazol-1-yl)-3h-benzimidazol-5-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(N2)N3N=C(C)C=C3)C2=C1 JHSPFPIXWVTTAA-UHFFFAOYSA-N 0.000 description 1
- CZPRHQWMFUDXEY-UHFFFAOYSA-N 4-methyl-3-[2-(4-methyl-1,3-oxazol-5-yl)-1,3-benzoxazol-6-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C3=C(N=CO3)C)C2=C1 CZPRHQWMFUDXEY-UHFFFAOYSA-N 0.000 description 1
- FLXOYHPHHSLXTD-UHFFFAOYSA-N 4-methyl-3-[2-(4-methylimidazol-1-yl)-1,3-benzoxazol-6-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)N3C=C(C)N=C3)C2=C1 FLXOYHPHHSLXTD-UHFFFAOYSA-N 0.000 description 1
- HHRXOEBTNKDAJV-UHFFFAOYSA-N 4-methyl-3-[2-(4-methylpiperazin-1-yl)-1,3-benzoxazol-5-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(OC(=N2)N3CCN(C)CC3)C2=C1 HHRXOEBTNKDAJV-UHFFFAOYSA-N 0.000 description 1
- ASELOHXKWDJOFE-UHFFFAOYSA-N 4-methyl-3-[2-(4-methylpiperazin-1-yl)-3h-benzimidazol-5-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(N2)N3CCN(C)CC3)C2=C1 ASELOHXKWDJOFE-UHFFFAOYSA-N 0.000 description 1
- WERIVQKXUMHWLX-UHFFFAOYSA-N 4-methyl-3-[2-(4-methylpyrazol-1-yl)-1,3-benzoxazol-5-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(OC(=N2)N3N=CC(C)=C3)C2=C1 WERIVQKXUMHWLX-UHFFFAOYSA-N 0.000 description 1
- XIDRXOLUZQRNFE-UHFFFAOYSA-N 4-propyl-3-(2-pyridin-4-yl-1,3-benzoxazol-5-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CCCC1CC(=O)NN=C1C1=CC=C(OC(=N2)C=3C=CN=CC=3)C2=C1 XIDRXOLUZQRNFE-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- XKVUYEYANWFIJX-UHFFFAOYSA-N 5-methyl-1h-pyrazole Chemical compound CC1=CC=NN1 XKVUYEYANWFIJX-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- WZZOXGVXYPZGSQ-UHFFFAOYSA-N 6-acetamido-N-[2-hydroxy-5-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]pyridine-3-carboxamide Chemical compound OC1=C(C=C(C=C1)C=1C(CC(NN=1)=O)C)NC(=O)C=1C=CC(=NC=1)NC(=O)C WZZOXGVXYPZGSQ-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- GRYYVLSYNHUDRC-UHFFFAOYSA-N CC1CC(NN=C1C1=CC2=C(N=C(N2)N2N=CC(=C2O)C)C=C1)=O Chemical compound CC1CC(NN=C1C1=CC2=C(N=C(N2)N2N=CC(=C2O)C)C=C1)=O GRYYVLSYNHUDRC-UHFFFAOYSA-N 0.000 description 1
- OEKHBIBEGBUWID-UHFFFAOYSA-N COC(CC(C(=O)C1=CC2=C(N=C(N2)N2N=CC(=C2O)C)C=C1)C)=O Chemical compound COC(CC(C(=O)C1=CC2=C(N=C(N2)N2N=CC(=C2O)C)C=C1)C)=O OEKHBIBEGBUWID-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical compound CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AZBSXPVSRIJUAG-UHFFFAOYSA-N N-[2-amino-4-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]-2,6-dichloropyridine-4-carboxamide Chemical compound NC1=C(C=CC(=C1)C=1C(CC(NN=1)=O)C)NC(=O)C1=CC(=NC(=C1)Cl)Cl AZBSXPVSRIJUAG-UHFFFAOYSA-N 0.000 description 1
- HUQLCJRAARLBLT-UHFFFAOYSA-N N-[2-amino-4-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]furan-2-carboxamide Chemical class NC1=C(C=CC(=C1)C=1C(CC(NN=1)=O)C)NC(=O)C=1OC=CC=1 HUQLCJRAARLBLT-UHFFFAOYSA-N 0.000 description 1
- GWRHLGBUTURIHL-UHFFFAOYSA-N N-[2-amino-4-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]pyrazine-2-carboxamide Chemical compound N1=C(C=NC=C1)C(=O)NC1=C(C=C(C=C1)C=1C(CC(NN=1)=O)C)N GWRHLGBUTURIHL-UHFFFAOYSA-N 0.000 description 1
- HNNYLPSSSGCYOO-UHFFFAOYSA-N N-[2-amino-4-(6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]thiophene-2-carboxamide Chemical compound NC1=C(C=CC(=C1)C=1CCC(NN=1)=O)NC(=O)C=1SC=CC=1 HNNYLPSSSGCYOO-UHFFFAOYSA-N 0.000 description 1
- NYRIQGBYQKHBKA-UHFFFAOYSA-N N-[2-amino-4-(6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]thiophene-3-carboxamide Chemical compound NC1=C(C=CC(=C1)C=1CCC(NN=1)=O)NC(=O)C1=CSC=C1 NYRIQGBYQKHBKA-UHFFFAOYSA-N 0.000 description 1
- CJKWEMVDCNWJJI-UHFFFAOYSA-N N-[2-hydroxy-4-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]-4-methyl-1,3-oxazole-5-carboxamide Chemical compound OC1=C(C=CC(=C1)C=1C(CC(NN=1)=O)C)NC(=O)C1=C(N=CO1)C CJKWEMVDCNWJJI-UHFFFAOYSA-N 0.000 description 1
- KSSGGKQKCUUEOD-UHFFFAOYSA-N N-[2-hydroxy-4-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]furan-2-carboxamide Chemical compound OC1=C(C=CC(=C1)C=1C(CC(NN=1)=O)C)NC(=O)C=1OC=CC=1 KSSGGKQKCUUEOD-UHFFFAOYSA-N 0.000 description 1
- IQAIWBGBKVEWPO-UHFFFAOYSA-N N-[2-hydroxy-4-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]pyrazine-2-carboxamide Chemical compound OC1=C(C=CC(=C1)C=1C(CC(NN=1)=O)C)NC(=O)C1=NC=CN=C1 IQAIWBGBKVEWPO-UHFFFAOYSA-N 0.000 description 1
- JVMSQUQENCNDEM-UHFFFAOYSA-N N-[2-hydroxy-4-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]pyridine-2-carboxamide Chemical compound OC1=C(C=CC(=C1)C=1C(CC(NN=1)=O)C)NC(=O)C1=NC=CC=C1 JVMSQUQENCNDEM-UHFFFAOYSA-N 0.000 description 1
- HQPUHVNGUVWJJO-UHFFFAOYSA-N N-[2-hydroxy-4-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]pyridine-4-carboxamide Chemical compound OC1=C(C=CC(=C1)C=1C(CC(NN=1)=O)C)NC(=O)C1=CC=NC=C1 HQPUHVNGUVWJJO-UHFFFAOYSA-N 0.000 description 1
- JOLUKSVKRMVLLV-UHFFFAOYSA-N N-[2-hydroxy-4-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]pyrimidine-5-carboxamide Chemical compound OC1=C(C=CC(=C1)C=1C(CC(NN=1)=O)C)NC(=O)C=1C=NC=NC=1 JOLUKSVKRMVLLV-UHFFFAOYSA-N 0.000 description 1
- FQLDFMGHVKENGO-UHFFFAOYSA-N N-[2-hydroxy-4-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]thiophene-3-carboxamide Chemical compound OC1=C(C=CC(=C1)C=1C(CC(NN=1)=O)C)NC(=O)C1=CSC=C1 FQLDFMGHVKENGO-UHFFFAOYSA-N 0.000 description 1
- ZAPYWRIFQWPWQF-UHFFFAOYSA-N N-[2-hydroxy-4-(6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]pyridine-2-carboxamide Chemical compound OC1=C(C=CC(=C1)C=1CCC(NN=1)=O)NC(=O)C1=NC=CC=C1 ZAPYWRIFQWPWQF-UHFFFAOYSA-N 0.000 description 1
- LFSBFUVEHHUAPY-UHFFFAOYSA-N N-[2-hydroxy-5-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]furan-2-carboxamide Chemical class OC1=C(C=C(C=C1)C=1C(CC(NN=1)=O)C)NC(=O)C=1OC=CC=1 LFSBFUVEHHUAPY-UHFFFAOYSA-N 0.000 description 1
- ZVSVTTNZOOPVPW-UHFFFAOYSA-N N-[2-hydroxy-5-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]pyridine-4-carboxamide Chemical class OC1=C(C=C(C=C1)C=1C(CC(NN=1)=O)C)NC(=O)C1=CC=NC=C1 ZVSVTTNZOOPVPW-UHFFFAOYSA-N 0.000 description 1
- SJMYSBVNSBHXFS-UHFFFAOYSA-N N-[2-hydroxy-5-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]thiophene-3-carboxamide Chemical class OC1=C(C=C(C=C1)C=1C(CC(NN=1)=O)C)NC(=O)C1=CSC=C1 SJMYSBVNSBHXFS-UHFFFAOYSA-N 0.000 description 1
- IPLUQJBWDMVRDP-UHFFFAOYSA-N N-[2-hydroxy-5-(6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]-4-methyl-1,3-oxazole-5-carboxamide Chemical class OC1=C(C=C(C=C1)C=1CCC(NN=1)=O)NC(=O)C1=C(N=CO1)C IPLUQJBWDMVRDP-UHFFFAOYSA-N 0.000 description 1
- WKFBHMWVFITLKI-UHFFFAOYSA-N N-[2-hydroxy-5-(6-oxo-4-propyl-4,5-dihydro-1H-pyridazin-3-yl)phenyl]pyridine-4-carboxamide Chemical compound OC1=C(C=C(C=C1)C=1C(CC(NN=1)=O)CCC)NC(=O)C1=CC=NC=C1 WKFBHMWVFITLKI-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical class O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- GYNWJIUVGYDGQS-UHFFFAOYSA-N ethyl 4-[6-(4-methyl-6-oxo-4,5-dihydro-1h-pyridazin-3-yl)-1,3-benzoxazol-2-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2O1 GYNWJIUVGYDGQS-UHFFFAOYSA-N 0.000 description 1
- DROVXVPSOQWXQP-UHFFFAOYSA-N ethyl 4-[6-(6-oxo-4,5-dihydro-1h-pyridazin-3-yl)-1,3-benzoxazol-2-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C1=NC2=CC=C(C=3CCC(=O)NN=3)C=C2O1 DROVXVPSOQWXQP-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- RIKMMFOAQPJVMX-UHFFFAOYSA-N fomepizole Chemical compound CC=1C=NNC=1 RIKMMFOAQPJVMX-UHFFFAOYSA-N 0.000 description 1
- 229960004285 fomepizole Drugs 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- XVOXPOMAKXCLMP-UHFFFAOYSA-N methyl 3-methyl-4-[2-(4-methylpiperazin-1-yl)-3H-benzimidazol-5-yl]-4-oxobutanoate Chemical compound COC(CC(C(=O)C1=CC2=C(N=C(N2)N2CCN(CC2)C)C=C1)C)=O XVOXPOMAKXCLMP-UHFFFAOYSA-N 0.000 description 1
- VVKGYSXTHOUSLW-UHFFFAOYSA-N methyl 3-methyl-4-oxo-4-(2-pyrrolidin-1-yl-3H-benzimidazol-5-yl)butanoate Chemical compound COC(CC(C(=O)C1=CC2=C(N=C(N2)N2CCCC2)C=C1)C)=O VVKGYSXTHOUSLW-UHFFFAOYSA-N 0.000 description 1
- GZWMWVCKGYXHAZ-UHFFFAOYSA-N methyl 3-methyl-4-oxo-4-[2-(1H-pyrrol-2-yl)-3H-benzimidazol-5-yl]butanoate Chemical compound N1C(=CC=C1)C=1NC2=C(N=1)C=CC(=C2)C(C(CC(=O)OC)C)=O GZWMWVCKGYXHAZ-UHFFFAOYSA-N 0.000 description 1
- KUUCNYFUJPWRJZ-UHFFFAOYSA-N methyl 3-methyl-4-oxo-4-[2-(2-oxoimidazolidin-1-yl)-3H-benzimidazol-5-yl]butanoate Chemical compound COC(CC(C(=O)C1=CC2=C(N=C(N2)N2C(NCC2)=O)C=C1)C)=O KUUCNYFUJPWRJZ-UHFFFAOYSA-N 0.000 description 1
- MPHWBQQPAIUPAC-UHFFFAOYSA-N methyl 3-methyl-4-oxobutanoate Chemical compound COC(=O)CC(C)C=O MPHWBQQPAIUPAC-UHFFFAOYSA-N 0.000 description 1
- IPHXWCLWSJPOGN-UHFFFAOYSA-N methyl 4-(2-imidazol-1-yl-3H-benzimidazol-5-yl)-3-methyl-4-oxobutanoate Chemical compound COC(CC(C(=O)C1=CC2=C(N=C(N2)N2C=NC=C2)C=C1)C)=O IPHXWCLWSJPOGN-UHFFFAOYSA-N 0.000 description 1
- FUOKKYNLHAWDOY-UHFFFAOYSA-N methyl 4-[2-(4-acetylpiperazin-1-yl)-3H-benzimidazol-5-yl]-3-methyl-4-oxobutanoate Chemical compound COC(CC(C(=O)C1=CC2=C(N=C(N2)N2CCN(CC2)C(C)=O)C=C1)C)=O FUOKKYNLHAWDOY-UHFFFAOYSA-N 0.000 description 1
- OXIYNWVEQRMACG-UHFFFAOYSA-N methyl 4-[2-(azepan-1-yl)-3H-benzimidazol-5-yl]-3-methyl-4-oxobutanoate Chemical compound N1(CCCCCC1)C=1NC2=C(N=1)C=CC(=C2)C(C(CC(=O)OC)C)=O OXIYNWVEQRMACG-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- JPCYSYNQDLWWHK-UHFFFAOYSA-N n-[5-[5-(4-methyl-6-oxo-4,5-dihydro-1h-pyridazin-3-yl)-1,3-benzoxazol-2-yl]pyridin-2-yl]acetamide Chemical compound CC1CC(=O)NN=C1C1=CC=C(OC(=N2)C=3C=NC(NC(C)=O)=CC=3)C2=C1 JPCYSYNQDLWWHK-UHFFFAOYSA-N 0.000 description 1
- LTUZASMLIZCACN-UHFFFAOYSA-N n-[5-[6-(4-methyl-6-oxo-4,5-dihydro-1h-pyridazin-3-yl)-1,3-benzoxazol-2-yl]pyridin-2-yl]acetamide Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3C=NC(NC(C)=O)=CC=3)C2=C1 LTUZASMLIZCACN-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000002071 phenylalkoxy group Chemical group 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- JCBJVAJGLKENNC-UHFFFAOYSA-M potassium ethyl xanthate Chemical compound [K+].CCOC([S-])=S JCBJVAJGLKENNC-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- YNVOMSDITJMNET-UHFFFAOYSA-N thiophene-3-carboxylic acid Chemical compound OC(=O)C=1C=CSC=1 YNVOMSDITJMNET-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
Abstract
Die Erfindung betrifft neue Pyridazinone sowie ein Verfahren zur Herstellung dieser Verbindungen der allgemeinen Formel I, in der X, R1 und R2 die in den Beschreibungsunterlagen genannte Bedeutung haben. Aufgrund ihrer pharmakologischen Eigenschaften eignen sich die erfindungsgemaess hergestellten Verbindungen der allgemeinen Formel I und deren optisch aktive Antipoden sowie deren physiologisch vertraegliche Saeureadditionssalze mit anorganischen oder organischen Saeuren zur Behandlung der chronischen Herzinsuffizienz oder der Angina pectoris und/oder zur Prophylaxe arterieller Thromboembolien und arterieller Verschlusskrankheiten. Formel IThe invention relates to novel pyridazinones and to a process for the preparation of these compounds of the general formula I in which X, R 1 and R 2 have the meaning given in the specification. Because of their pharmacological properties, the compounds of general formula I and their optically active antipodes and their physiologically acceptable acid addition salts with inorganic or organic acids are suitable for the treatment of chronic heart failure or angina pectoris and / or for the prophylaxis of arterial thromboembolism and arterial occlusive diseases. Formula I
Description
Anwendungsgebiet der Erfindung-'-' Y.y: ':";;:.,·:;;.; .."" :,-; .· · -,:; Field of the Invention -'- 'Yv'"";;..;;: ·... "
"''Die Erfindung betrifft ein Verfahren zur Hersteilung neuer - Pyridazinone, die in Arzneimitteln, als Wirkstoff . eingesetzir- 'werden· .'.": -. ·.'-:.- -; ~^:~ ":\ix ^-:.\ '^ :'i-::- ,-'-. - -' : ' ' "'--.'. ..<-. -t .. -. :'- * - :.: r-~:*2,y" The invention relates to a process for the preparation of novel pyridazinones which are used in medicaments as active ingredient. : -. ·. '-: .- -; ~ ^ : ~ " : \ i x ^ -:. \ '^ : ' i - :: -, -'-. - - ':''"' -. '. .. <-. -t .. -. : '- * -:.: r- ~ : * 2, y "
Charakteristik der bekannten technischen Lösungen \~ ^ v'-- Characteristic of the known technical solutions \ ~ ^ v '-
In der US-Patentschrift .4.026.891 sowie in den Europäischen Patentschriften 0.008.391 und O.Q34*.743 werden bereits'Pyri- / dazinone beschrieben, welche wertvolle pharmakologische Eigen-; schäften'aufweisen, insbesondere cardiotonische, eine,Wirkung auf den Blutdruck und/oder antithrombotische Wirkungen. .; - "US Pat. No. 4,026,891 and European Patents No. 0,008,391 and O.Q34 * .743 already describe pyridazoline which has valuable pharmacological properties; have, in particular, cardiotonic, an effect on the blood pressure and / or antithrombotic effects. . - "
, Ziel der Erfindung / ', ' . .:. - " ' ·. · - -' : r . , Object of the invention / ','. .:. - '' ·. · - - ' : r .
- Es ist das Ziel, der erfindung neue Verbindungen zu schaffen, .die in-Arzneimitteln wertvolle pharmakologische Eigenschaften, insbesondere scardiotonische Wirkungen aufweisen. ~">. ~ ' - ;-.·It is the object of the invention to provide novel compounds which have valuable pharmacological properties, in particular s cardiotonic effects. ~ ">. ~ ' -; -. ·
Darlegung des Wesens der Erfindung . ; " ·'- .'-'"''"'. . Explanation of the essence of the invention . ; "· '- .'-'"''''.
Der Erfindung liegt^die Aufgabe zugrunde, 'ein Verfahren zur . Herstellung von neuen Pyridazinonen, welche'"sich von den Ii- ^eraturbekannten Pyridazinonen durch den über ein Stickstoffatom oder über ein Kohlenstoffatom gebundenen gsättigten oderThe invention is based on the object 'a method for. Preparation of new pyridazinones which are "pyridazinones" which are known from the pyridazinones and are bonded by a nitrogen atom or a carbon atom
"N"N
(V. M19 85* 852881(V. M19 85 * 852881
aromatischen heterocyclischen Rest in 2-Stellung unterscheiden, und deren Säureadditionssalze, insbesondere deren physiologisch'' verträgliche. Säureadditibnssalze mit anorganischen. oder organischen Säuren', -zu entwickeln." "...-:. ; '/ -'- :' ' -"'/ distinguish aromatic heterocyclic radical in the 2-position, and their acid addition salts, in particular their physiologically '' compatible. Acid addition salts with inorganic. or organic acids'. "" ...- :. ; '/ -'-:''-"' /
Es wurde' gefunden, daß. die neuen Pyridazinone der. allgemeinen Formel . ' ' .. "-.'-'/. ·. ' '- Y;;'-'··'' Y' · '-. "-".'.,-'. '.. ' Y -^ '.' ... . : It was found that. the new pyridazinone the. general formula. '' .. "-.'- '.'., -. '/ *''-Y' -... '··''Y' · '- -""' .. 'Y - ^ '.' ... :
;" -.' . " '- " ' '.;; :, (D ; "-." . "'- " ''.;;:, (D
"worin'· . ..·:;·. "' - ·-.^ -. :"~-\-- ' --:-. .'.' ; -.:.' ..'^ '' - :...·; ^ '. '.." " - ' ·' ' '- ". - -.···.- -X eine gegebenenfalls durch eine Älkyl- oder Phenylalkylgrup-pe substituierte Iminogruppe, ein Sauerstoff- oder Schwefelatom, . .. - ' '-. ; ::·; ' ' _. .''" - '.'. ;- ':'"/ ·'·',; ' - · s. . '^, " - ' '"where" · · · · · · · · "" - · -. ^ -. : "~ - \ - '-: -. ; -:: ' .. '^''- : ... ·; ^'. '.. ""-' · '''-". - -. ··· .- -X is an imino group optionally substituted by an alkyl or phenylalkyl group, an oxygen or sulfur atom,. .. - ' ' -. ; : ·; '' _. . ''"-'.'.; - ':'" / · '·',;'- · s. , '^, "-''
E^ "einen über ein Stickstoffatom gebundenen gesättigten 5-bis 7-gliedrigen Alkyleniminoring oder- einen über ein Kohlenstoffatom gebundenen 5- bis 7-güedrigen gesättigten Imino-, N-Alkyl-imino-,.. 1-Phenylalkyl-imino-, U-Alkanoyl-imino-' ·, oder H-Alkoxycarbonyl-imino-alkylrenring, wobei die vorstehend erwähnten Ringe im Kohlenstoffgerüst durch ein oder zwei Alkylgruppen substituiert'und eine Methylengruppe in 4-Stellung eines 6--oder 7-gliedrigen Ringes durch ein Sauerstoff- oder Schwefelatom, eine Sulfinyl-, Sulfonyl-, Imino-, Alkylimino-, Phenylalkylimino-, Alkoxycarbonyl-j.mino- oder Alkanoyliminogruppe ersetzt sein kann, einen gegebenenfalls durch eine oder zv/ei Alkylgruppen über ein Stickstoffatom gebundenen gesättigten 5- bis 7-gliedrigen Alkyleniminoring, in dem eine -CHpCHn-Gruppe durch eine -WH-CO-Gruppe ersetzt ist, wobei die GO-Gruppe dieser -IJH-CO-Gruppe mit dem bereits vorhandenen H-Atom verknüpft ist, einen über ein Stickstoffatom gebun-E ^ "a bonded via a nitrogen saturated 5- to 7-membered Alkyleniminoring or a bonded via a carbon 5- to 7-membered saturated imino, N-alkyl-imino, .. 1-phenylalkyl-imino, U Alkanoyl-imino- '' or H-alkoxycarbonyl-imino-alkylene ring, wherein the above-mentioned rings in the carbon skeleton substituted by one or two alkyl groups' and a methylene group in the 4-position of a 6- or 7-membered ring by an oxygen - or sulfur atom, a sulphinyl, sulphonyl, imino, alkylimino, Phenylalkylimino-, alkoxycarbonyl or j.mino- Alkanoyliminogruppe may be substituted, an optionally linked by one or zv / ei alkyl via a nitrogen atom saturated 5- to 7 -membered alkyleneimino ring in which a -CHpCHn group is replaced by a -WH-CO group, the GO group of this -IJH-CO group being linked to the already present H atom, a nitrogen atom bonded via a nitrogen atom.
denen 5-gliedrigen hetero aromatischen Ring, 'welcher zusätzlich ein Sauerstoff- oder Schwefelatom, e"xn oder zwei Stickstoffatome, ein Sauerstoff- oder Schwefelatom-und ein Stickstoffatom enthalten kann,, wobei der heteroaromatische Ring durch ein oder zwei Alky!gruppen und * im PaIIe der Pyrazole auch durch eine üydroxygruppe und- eine Alkylgruppe substituiert sein kann, einen über ein Kohlenstoffatom gebundenen 5- oder 6-gliedrigeh heteroaromatischen Ring, welcher ein Sauerstoffoder Schwefelatom, ein, zwei oder drei Stickstoffatome, ein Sauerstoff-,oder Schwefelatom und ein oder.zwei Stickstoffatome enthalten kann, wobei die heteroaromatischen Ringe durch ein oder, zwei Alky !gruppen*., durch eine Amino- oder Alkanoylaminogruppe und im Falle der Pyridine auch durch ein oder zwei Halogenatome oder durch ein Halogenatom und eine Amino- oder Morpholinogruppe substituiert sein können, und Ro ein Wasserstoffatom oder eine Alkylgruppe, wobei alle vorstehend erwähnten Alkyl-,--.Alkanoyl- oder Alkoxygruppen jeweils 1 bis 3 Kohlenstoff.atome enthalten können; bedeuten, wie folgt erfindungsgemäß hergestellt werden.5-membered heteroaromatic ring, which may additionally contain an oxygen or sulfur atom, e "xn or two nitrogen atoms, an oxygen or sulfur atom and a nitrogen atom, where the heteroaromatic ring is represented by one or two alkyl groups and in the PaIIe of the pyrazoles may also be substituted by a hydroxy group and- an alkyl group, a bound via a carbon atom 5- or 6-membered heteroaromatic ring, which is an oxygen or sulfur atom, one, two or three nitrogen atoms, an oxygen or sulfur atom and or.two may contain nitrogen atoms, the heteroaromatic rings being substituted by one or two alkyl groups, by an amino or alkanoylamino group and in the case of the pyridines also by one or two halogen atoms or by a halogen atom and an amino or morpholino group and Ro is a hydrogen atom or an alkyl group, wherein all of the aforementioned alkyl, -. alkano yl or alkoxy groups can each contain 1 to 3 Kohlenstoff.atome; mean, as prepared according to the invention.
Cyclisierung einer gegebenenfalls im Reaktionsgemisch gebildeten Verbindung der allgemeinen Formel .Cyclization of a compound of the general formula optionally formed in the reaction mixture.
IT-HIT H
, (II), (II)
in derin the
Rp wie eingangs definiert ist,Rp as defined above,
einer der Reste A oder B eineone of the radicals A or B is a
2I Z2 2 I Z 2
R-, ' - C-X - Gruppe undR, '- C-X - group and
1I Ϊ2 ?3 1IΪ2 ? 3
der andere der Reste A oder B eine Aminogruppe oder eine Zthe other of the radicals A or B is an amino group or a Z
R,1 - C-NH - oder R1' -C=N- GruppeR, 1 - C-NH - or R 1 '-C = N- group
bedeuten, wobei X wie eingangs definiert ist und R-. ' einen der für R-, eingangs erwähnten über einen Kohlenstoffatom gebundenen Reste darstellt, Z, und Z», die gleich oder verschieden sein können, nukleophile Austrittsgruppen wie gegebenenfalls substituierte Amino-, Alkoxy-, Phenylalkoxy-, Phenoxy-, Alkylmercapto-, Phenylalkylmercapto- oder Phenylthiogruppen oderwhere X is as defined above and R-. 'represents one of the above-mentioned carbon-bonded radicals R, Z, and Z', which may be the same or different, nucleophilic leaving groups such as optionally substituted amino, alkoxy, phenylalkoxy, phenoxy, alkylmercapto, phenylalkylmercapto or phenylthio groups or
Z-, und Z- zusammen ein Sauerstoff- oder Schwefelatom, eine gegebenenfalls durch eine Alkyl- oder Phenylalky!gruppe substituierte Iminogruppe, wobei die vorstehend erwähnten Alkylteile jeweils 1 bis 3 Kohlenstoffatome enthalten können, oder eine Alkylendioxigruppe mit 2 oder 3 Kohlenstoffatomen undZ- and Z- together represent an oxygen or sulfur atom, an imino group optionally substituted by an alkyl or phenylalkyl group, where the abovementioned alkyl moieties may each contain 1 to 3 carbon atoms, or an alkylenedioxy group having 2 or 3 carbon atoms and
Z-, die für Z, eingangs erwähnten Bedeutungen oder eine Imidazolylgruppe, ein Chlor-, Brom- oder Jodatom bedeuten.Z-, which mean Z, the meanings mentioned above or an imidazolyl group, a chlorine, bromine or iodine atom.
Für Z^ und Z2 kommt beispielsweise jeweils die der Methoxy-, Ethoxy-, Propoxy-, Benzyloxy-, Methylmercapto-, Ethylmercapto-, Propylmercapto-, Phenylmercapto- oder Benzylmercaptogruppe undFor Z ^ and Z 2 , for example, each of the methoxy, ethoxy, propoxy, benzyloxy, methylmercapto, ethylmercapto, propylmercapto, phenylmercapto or Benzylmercaptogruppe and
für Z3 die des Chlor-, Brom- oder Jodatoms, der Methoxy-, Ethoxy-, Phenoxy-, Methylmercapto-, Ethylmercapto-, Phenyl-for Z 3 those of the chlorine, bromine or iodine atom, the methoxy, ethoxy, phenoxy, methylmercapto, ethylmercapto, phenyl
mercapto-, Benzylmercapto- oder Imidazolylgruppe in Betracht.mercapto, benzylmercapto or imidazolyl group into consideration.
Die Umsetzung wird zweckmäßigerweise in einem Lösungsmittel 5 oder Losungsmittelgemisch wie Ethanol, Isopropanol, Eisessig, Tetrahydrofuran, Dioxan, Benzol, Toluol, Xylol, Chlorbenzol, Glycol, Glycolmonomethylather, Glycoldimethyläther, Diäthylenglycoldimethylether, Dimethylformamid, Tetralin oder Sulfolan gegebenenfalls in Gegenwart eines Kondensationsmittels wie Phosphoroxychlorid, Thionylchlorid, Sulfurylchlorid, Salzsäure, Schwefelsäure, Phosphorsäure, Polyphosphorsäure, p-Toluolsulfonsäure, Eisessig, Essigsäureanhydrid, N,N1-Dicyclohexyl-carbodiimid, Carbonyldiimidazol, Kaliummethylat oder Kalium-tert.butylat bei Temperatüren zwischen 0 und 3000C, vorzugsweise jedoch bei der Siedetemperatur des Reaktionsgemisches, z.B. bei Temperaturen zwischen 50 und 2850C, durchgeführt. Die Umsetzung kann jedoch auch in der Schmelze durchgeführt werden.The reaction is conveniently carried out in a solvent or solvent mixture such as ethanol, isopropanol, glacial acetic acid, tetrahydrofuran, dioxane, benzene, toluene, xylene, chlorobenzene, glycol, glycol monomethyl ether, glycol dimethyl ether, diethylene glycol dimethyl ether, dimethylformamide, tetralin or sulfolane, optionally in the presence of a condensing agent such as phosphorus oxychloride, Thionyl chloride, sulfuryl chloride, hydrochloric acid, sulfuric acid, phosphoric acid, polyphosphoric acid, p-toluenesulfonic acid, glacial acetic acid, acetic anhydride, N, N 1 -dicyclohexyl-carbodiimide, carbonyldiimidazole, potassium or potassium tert-butoxide at temperatures between 0 and 300 0 C, but preferably at the boiling point of the reaction mixture, for example at temperatures between 50 and 285 0 C, performed. However, the reaction can also be carried out in the melt.
Bedeutet R1 einen der eingangs erwähnten über ein Kohlenstoffatom gebundenen Reste, so wird die Umsetzung besonders vorteilhaft in einem Überschuß des für die Herstellung einer entsprechenden Verbindung der allgemeinen Formel II eingesetzten Acylierungsmittels, z.B. mit einem Überschuß des eingesetzten Nitrils, Anhydrids, Esters, Thioesters, Orthoesters, Amids, Thioamids, Halogenids oder Methojodids durchgeführt.If R 1 denotes one of the abovementioned radicals bonded via a carbon atom, then the reaction is particularly advantageously carried out in an excess of the acylating agent used for the preparation of a corresponding compound of general formula II, for example with an excess of the nitrile, anhydride, ester, thioester, Orthoesters, amides, thioamides, halides or Methojodids performed.
b) Umsetzung einer Carbonsäure der allgemeinen Formelb) reaction of a carboxylic acid of the general formula
C -CH2-L CH2- COOH ,(III)C-CH 2 -L CH 2 -COOH, (III)
in der in the
R, und R2 wie eingangs definiert sind,R and R 2 are as defined above,
oder deren reaktionsfähige Säurederivate wie deren Ester, Amide oder Halogenide mit Hydrazin.or their reactive acid derivatives such as their esters, amides or halides with hydrazine.
Die Umsetzung wird zweckmäßigerweise in einem Lösungsmittel wie Methanol, Äthanol, Isopropanol, Eises-sig, Propionsäure und/oder in einem Überschuß von Hydrazin bzw. Hydrazin-hydrat bei Temperaturen zwischen 0 und 2000C, z.B. bei Temperaturen zwischen 20 und 15O0C, vorzugsweise jedoch bei der Siedetemperatur des Reaktionsgemisches, und gegebenenfalls in Gegenwart einer Säure wie Schwefelsäure oder p-Toluolsulfonsäure als Kondensationsmittel durchgeführt. Die Umsetzung kann jedoch auch ohne Lösungsmittel durchgeführt werden.The reaction is conveniently carried out in a solvent such as methanol, ethanol, isopropanol, ice-sig, propionic acid and / or in an excess of hydrazine or hydrazine hydrate at temperatures between 0 and 200 0 C, for example at temperatures between 20 and 15O 0 C. but preferably at the boiling temperature of the reaction mixture, and optionally in the presence of an acid such as sulfuric acid or p-toluenesulfonic acid as a condensing agent. However, the reaction can also be carried out without a solvent.
c) Zur Herstellung von Verbindungen der allgemeinen Formel I/ in der R, einen der eingangs erwähnten über ein Stickstoffatom gebundenen Reste darstellt:c) For the preparation of compounds of the general formula I in which R 1 represents one of the radicals mentioned above bonded via a nitrogen atom:
Umsetzung einer Verbindung der allgemeinen FormelReaction of a compound of the general formula
,(IV)(IV)
in derin the
R2 und X wie eingangs definiert sind undR 2 and X are as defined above and
z. eine nukleophil austauschbare Gruppe wie ein Halogenatom, eine Sulfogruppe oder eine substituierte Mercaptogruppe, z.B. ein Chlor- oder Bromatom, eine Sulfo-, Methylthio-, Ethylthio-, Phenylthio-, 2-Nitrophenylthio-, 4-Nitrophenylthio-, 2,4-Dinitrophenylthio-, Pyridin-4-thio- oder Pyridin-2-thiogruppe bedeutet, mit einem Amin der allgemeinen Formelz. a nucleophile-exchangeable group such as a halogen atom, a sulfo group or a substituted mercapto group, e.g. a chlorine or bromine atom, a sulfo, methylthio, ethylthio, phenylthio, 2-nitrophenylthio, 4-nitrophenylthio, 2,4-dinitrophenylthio, pyridine-4-thio or pyridine-2-thio group, with an amine of the general formula
H - R1" ,(V)H - R 1 ", (V)
in derin the
R-," einen der für R1 eingangs erwähnten über ein Stickstoffatom gebundenen Rest darstellt.R-, "one of the above-mentioned radical R 1 bound via a nitrogen atom represents.
Die Umsetzung wird in der Schmelze oder in einem geeigneten Lösungsmittel wie Tetrahydrofuran, Dioxan, Dimethylformamid oder Dimethylsulfoxid gegebenenfalls in Gegenwart eines säurebindenden Mittels wie. Kaliumcarbonat oder Pyridin bei erhöhten Temperaturen, z.B. bei Temperaturen zwischen-50 und 2000C, vorzugsweise jedoch bei Temperaturen zwischen 100 und 1800C, durchgeführt.The reaction is carried out in the melt or in a suitable solvent such as tetrahydrofuran, dioxane, dimethylformamide or dimethyl sulfoxide, optionally in the presence of an acid-binding agent such as. Potassium carbonate or pyridine at elevated temperatures, for example at temperatures between -50 and 200 0 C, but preferably at temperatures between 100 and 180 0 C performed.
d) Zur ,Herstellung von Verbindungen der allgemeinen Formel I, in der X ein Sauerstoffatom oder eine gegebenenfalls durch eine Alkyl- oder Phenylalkylgruppe substituierte Iminogruppe darstellt:d) For the preparation of compounds of general formula I in which X represents an oxygen atom or an imino group optionally substituted by an alkyl or phenylalkyl group:
Hydrierung einer Verbindung der allgemeinen FormelHydrogenation of a compound of the general formula
,(VI)(VI)
//I ^ I I '// I ^ I '
in derin the
R1 und R2 wie eingangs definiert sind und X1 ein Sauerstoffatom oder eine gegebenenfalls durch eine Alkyl- oder Phenylalkylgruppe substituierte Iminogruppe, wobei der Alkylteil jeweils 1 bis 3 Kohlenstoffatome enthalten kann, bedeutet.R 1 and R 2 are as defined above and X 1 is an oxygen atom or an optionally substituted by an alkyl or phenylalkyl imino group, wherein the alkyl moiety may each contain 1 to 3 carbon atoms, means.
Die katalytische Hydrierung wird in einem Lösungsmittel wie Methanol, Ethanol, Essigsäureäthylester, Eisessig oder Dimethylformamid mit Wasserstoff in Gegenwart eines Hydrierungskatalysators wie Raney-Nickel, Platin oder.Palladium/ Kohle bei Temperaturen zwischen 0 und 75°C, vorzugsweise jedoch bei Raumtemperatur, und bei einem Wasserstoffdruck von 1 bis 5 bar durchgeführt.The catalytic hydrogenation is carried out in a solvent such as methanol, ethanol, ethyl acetate, glacial acetic acid or dimethylformamide with hydrogen in the presence of a hydrogenation catalyst such as Raney nickel, platinum or .Palladium / carbon at temperatures between 0 and 75 ° C, but preferably at room temperature, and at a hydrogen pressure of 1 to 5 bar performed.
Erhält man erfindungsgemäß eine Verbindung der allgemeinen Formel I, in der R-^ eine Imino- und/oder Aminogruppe enthält, so kann diese mittels Alkanoylierung in eine entsprechende Verbindung der allgemeinen Formel I, in der R-, eine Alkanoylimino- und/oder Alkanoylaminogruppe enthält, übergeführt werden oderIf, according to the invention, a compound of the general formula I in which R 1 contains an imino and / or amino group can be prepared by alkanoylation into a corresponding compound of the general formula I in which R 1 is an alkanoylimino and / or alkanoylamino group contains, be transferred or
eine Verbindung der allgemeinen Formel I, in der R-, einen über ein Kohlenstoffatom gebundenen durch Halogenatome substituierten Pyridinrest darstellt, so kann diese mittels katalytischer Enthalogenierung und Hydrierung in eine Verbindung der allgemeinen Formel I, in der R, einen über ein Kohlenstoffatom gebundenen Piperidinorest darstellt, übergeführt werden, odera compound of the general formula I in which R- represents a pyridine radical which is bonded via a carbon atom and is substituted by halogen atoms, this can be represented by catalytic dehalogenation and hydrogenation in a compound of the general formula I in which R 1 is a piperidino radical bonded via a carbon atom , be transferred, or
eine Verbindung der allgemeinen Formel I, in der R-, einen über ein Kohlenstoffatom gebundenen durch ein oder zwei Halogenatome substituierten Pyridinrest darstellt, so kann diese durch Halogenaustausch in eine entsprechende Verbindung der allgemeinen Formel I7 in der R-, einen über ein Kohlenstoffatom gebundenen Pyridinrest darstellt, der durch eine Amino- oder Morpholinogruppe und gegebenenfalls durch ein Halogenatom substituiert ist, übergeführt werden.a compound of general formula I in which R- represents a pyridine radical substituted by one or two halogen atoms bonded via a carbon atom, this may be converted by halogen exchange into a corresponding compound of general formula I 7 in the R-, one bonded via a carbon atom Pyridine radical which is substituted by an amino or morpholino group and optionally substituted by a halogen atom, be converted.
Die nachträgliche Alkanoylierung wird zweckmäßigerweise in einem Lösungsmittel wie Methylenchlorid, Chloroform, Diethylether, Tetrahydrofuran, Dioxan, Benzol, Acetonitril oder Dimethylformamid mit einem entsprechenden Ester, Anhy-The subsequent alkanoylation is expediently carried out in a solvent such as methylene chloride, chloroform, diethyl ether, tetrahydrofuran, dioxane, benzene, acetonitrile or dimethylformamide with a corresponding ester, anhydride,
drid oder Säurehalogenid gegebenenfalls in Gegenwart eines säurebindenden Mittels wie Natriumcarbonat oder Pyridin oder mit einer entsprechenden Alkansäure in Gegenwart eines die Säure aktivierenden Mittels oder wasserentziehenden Mittels, z.B. in Gegenwart von Chlorameisensäureäthylester, Thionylchlorid, Phosphortrichlorid, N,N1-Dicyclohexylcarbodiimid, Ν,Ν1-Carbonyldiimidazol oder N,N1-Thionyldiimidazol bei Temperaturen zwischen 0 und 2000C, vorzugsweise jedoch bei Temperaturen zwischen 20 und 1000C, durchgeführt.anhydride or acid halide, optionally in the presence of an acid binding agent such as sodium carbonate or pyridine or with an appropriate alkanoic acid in the presence of an acid-activating agent or dehydrating agent, for example in the presence of ethyl chloroformate, thionyl chloride, phosphorus trichloride, N, N 1 -dicyclohexylcarbodiimide, Ν, Ν 1 Carbonyldiimidazole or N, N 1 -thionyldiimidazole at temperatures between 0 and 200 0 C, but preferably at temperatures between 20 and 100 0 C performed.
Die nachträgliche Enthalogenierung und Hydrierung wird in einem Lösungsmittel wie Methanol, Ethanol, Essigsäureäthylester, Eisessig oder Dimethylformamid mit Wasserstoff in Gegenwart eines Hydrierungskatalysators wie Platin oder Palladium/Kohle bei Temperaturen zwischen 0 und 75°C, vorzugsweise jedoch bei Raumtemperatur, und bei einem Wasserstoffdruck von 1 bis 5 bar durchgeführt.The subsequent dehalogenation and hydrogenation is carried out in a solvent such as methanol, ethanol, ethyl acetate, glacial acetic acid or dimethylformamide with hydrogen in the presence of a hydrogenation catalyst such as platinum or palladium / carbon at temperatures between 0 and 75 ° C, but preferably at room temperature, and at a hydrogen pressure of 1 to 5 bar performed.
Der nachträgliche Halogenaustausch wird mit Ammoniak oder Morpholin zweckmäßigerweise in einem Lösungsmittel wie Dioxan oder Dimethylformamid gegebenenfalls in einem Druckgefaß bei Temperaturen zwischen 50 und 1500C durchgeführt.The subsequent halogen exchange is advantageously carried out with ammonia or morpholine in a solvent such as dioxane or dimethylformamide optionally in a pressure vessel at temperatures between 50 and 150 0 C.
Die so erhaltenen Verbindungen der allgemeinen Formel I können aufgrund ihres optisch aktiven Kohlenstoffatoms in Position 4 oder 5 des Pyridazinon-Ringes, sofern R2 eine Alkylgruppe darstellt, in ihre optisch aktiven Antipoden mittels Racematspaltung aufgetrennt werden.The compounds of the general formula I thus obtained can be separated into their optically active antipodes by means of racemate resolution on the basis of their optically active carbon atom in position 4 or 5 of the pyridazinone ring, provided that R 2 represents an alkyl group.
Die Racematspaltung wird zweckmäßigerweise durch fraktionierte Kristallisation der entsprechenden Salze mit optisch aktiven Säuren, wie Weinsäure, Dibenzoylweinsäure, Apfelsäure, Camphersäure oder Camphersulfonsäure, oder durch Chromatographie an optisch aktiven Adsorbentien durchgeführt.The racemate resolution is conveniently carried out by fractional crystallization of the corresponding salts with optically active acids, such as tartaric acid, dibenzoyltartaric acid, malic acid, camphoric acid or camphorsulfonic acid, or by chromatography on optically active adsorbents.
9 A -AO- <- " 9 A -AO- <- "
Desweiteren können die erhaltenen Verbindungen der allgemei-'nen Formel I in ihre Säureadditionssalze, insbesondere für die pharmazeutische Anwendung in·ihre physiologisch verträglichen Salze mit anorganischen oder organischen Säuren, übergeführt werden. Als Säuren kommen hierfür beispielsweise Salzsäure, Bromwasserstoffsäure, Schwefelsäure, Phosphorsäure, Fumarsäure, Bernsteinsäure, Milchsäure, Zitronensäure, Weinsäure oder Maleinsäure in Betracht.Furthermore, the resulting compounds of general formula I can be converted into their acid addition salts, in particular for pharmaceutical use, into their physiologically tolerated salts with inorganic or organic acids. Examples of suitable acids are hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.
Die als Ausgangsstoffe verwendeten Verbindungen der allgemeinen Formeln II bis VI erhält man nach literaturbekannten Methoden bzw. sind literaturbekannt.The compounds of the general formulas II to VI used as starting materials are obtained by methods known from the literature or are known from the literature.
So erhält man beispielsweise eine entsprechende o-Diaminoverbindung der allgemeinen Formel II durch Umsetzung einer entsprechenden 3-(3-Nitro-4-acylamino-benzoyl)-propionsäure mit Hydrazin und anschließende Reduktion der Nitrogruppe (siehe US-A-4.026.891), eine entsprechende o-Hydroxy-acylamino- oder o-Mercapto-acylaminoverbindung der allgemeinen Formel II durch Umsetzung einer entsprechend substituierten 3-Benzoyl-propionsäure mit Hydrazin, gegebenenfalls anschließende Reduktion der Nitrogruppe und anschließende Acylierung der so erhaltenen Aminoverbindung.Thus, for example, a corresponding o-diamino compound of the general formula II is obtained by reacting a corresponding 3- (3-nitro-4-acylaminobenzoyl) propionic acid with hydrazine and subsequent reduction of the nitro group (see US Pat. No. 4,026,891), a corresponding o-hydroxy-acylamino or o-mercapto-acylamino compound of the general formula II by reacting a correspondingly substituted 3-benzoyl-propionic acid with hydrazine, optionally subsequent reduction of the nitro group and subsequent acylation of the amino compound thus obtained.
Eine als Ausgangsstoff verwendete Verbindung der allgemeinen Formel III erhält man durch Umsetzung eines entsprechenden ρ,α-Dihalogen-acetophenons mit einem entsprechenden Malonester. Das so erhaltene entsprechend substituierte 3-Benzoyl-propionsäurederivat wird anschließend verseift, decarboxyliert, nitriert, das Halogenatom durch eine Amino-, Hydroxy- oder Mercaptogruppe ersetzt, die Nitrogruppe reduziert und die so erhaltene Aminoverbindung nach Umsetzung mit einem entsprechenden Carbonsäurederivat zu der gewünschten Verbindung der allgemeinen Formel III umgesetzt.A compound of general formula III used as starting material is obtained by reacting a corresponding ρ, α-dihaloacetophenone with a corresponding malonic ester. The correspondingly substituted 3-benzoyl-propionic acid derivative thus obtained is then saponified, decarboxylated, nitrated, the halogen atom is replaced by an amino, hydroxy or mercapto group, the nitro group reduced and the amino compound thus obtained after reaction with a corresponding carboxylic acid derivative to the desired compound implemented the general formula III.
v- · : . 24Β 36 v - ·:. 24Β 36
Eine.als Ausgangsstoff verwendete Verbindung der allgemeinen Pormel 17 erhält man beispielsweise durch. Ringschluß eines . entsprechenden Thioharnstoffes oder durch Umsetzung einer entsprechenden o-Amino-hydroxy-"Verbindung mit Kaliumethylxanthogenat und anschließender Umsetzung des so erhaltenen 2-kercaptobenzoxazols mit einem entsprechenden Elektr.oph.il, ZoB. mit einem Alky!halogenid oder einem- ITitrohalogenbenzol»A compound used as starting material of the general Pormel 17 is obtained for example by. Ring closure of one. corresponding thiourea or by reaction of a corresponding o-amino-hydroxy "compound with potassium ethylxanthogenate and subsequent reaction of the 2-kercaptobenzoxazol thus obtained with a corresponding electrophosphile, ZoB., With an alkyl halide or a ITitrohalogenbenzol"
Eine als Ausgangstoff verwendete Verbindung der allgemeinen Formel VI erhält man durch Umsetzung eines entsprechenden Acrylsäurederivates mit Hydrazin.-Pur die bei der Definition der Reste X, R^ und R2 eingangs erwähnten Bedeutungen "kommt beispielsweise ..· '._ - ^ für X die des Sauerstoff- oder Schwefelatoms, der Imino-, Methylimino-, Ethylamino-, n-Propylimino-, Benzylimino-, 1-Phenylethylimino-, 2-Phenylethylimino- oder 3-Phenylpropylimino gruppe, ~" . . ; A compound of the general formula VI used as starting material is obtained by reacting a corresponding acrylic acid derivative with hydrazine.-Pur The meanings mentioned in the definition of the radicals X, R 1 and R 2 are , for example, ## STR3 ## that of the oxygen or sulfur atom, the imino, methylimino, ethylamino, n-propylimino, benzylimino, 1-phenylethylimino, 2-phenylethylimino or 3-phenylpropylimino group. , ;
für R^ die der 1-Pyrrolidinyl-, Piperidino-, T-Hexahydroazep-. inyl-,' 2-Methyl-i-pyrrolidinyl-, 3-Methyl-i-pyrrolidinyl-, 2-Methyl-piperidino-, 2-n-Propylpip.erid.ino7, 3-Methyl-piperidino-, 4-Methyl-piperidino-, 2-Ethyl-piperidino-, 4-Ethylpiperidino-, 4-Isopropyl-piperidino-, 2·, 6-Dimethyl-piperidino-, 3,5-Dimethyl-piperidino-, 1-Piperazinyl-, 4-Methyl-1-piperazinyl 4-Ethyl-T-piperazinyl-, 4-n-Propyl-1-piperazinyl-, 4-Benzyl-1-piperazinyl-, 4-Formy1-1-piperazinyl-, 4-Acety1-1rpiperazinyl-, 4-Propiony1-1-piperazinyl-, '4-Methoxycarbony1-1-piperazinyl-', 4-Ethoxycarbony1-1-piperazinyl-, 2-Pyrrolidinyl-, 3_Pyri<olidinyl-, 2-Piperidino-, 3-Piperidino-, 4-Piperidino-, N-Methyl-2-pyrrolidinyl-, N-Methyl-3-pyrrolidinyl,.N-Methyl-4-piperidino-, H-Ethyl-4-piperidino-, Ii-Isopropyl-4-piperidino-, H-Formyl-4-piperidino-, U-Acetyl-4-piperidinoj·, N-Propionyl-4-piperidino-, Morpholino-, Thiomor-pholino-, 1-Oxido-4-thiomorpholino-, 1,1-Dioxido^-thiomor-pholino-, Imidazolin-for R ^ the 1-pyrrolidinyl, piperidino, T-Hexahydroazep-. inyl, '2-methyl-i-pyrrolidinyl, 3-methyl-i-pyrrolidinyl, 2-methyl-piperidino, 2-n-propylpip.erid.ino7, 3-methylpiperidino, 4-methyl piperidino, 2-ethyl-piperidino, 4-ethyl-piperidino, 4-isopropyl-piperidino, 2 ·, 6-dimethyl-piperidino, 3,5-dimethyl-piperidino, 1-piperazinyl, 4-methyl 1-piperazinyl 4-ethyl-T-piperazinyl, 4-n-propyl-1-piperazinyl, 4-benzyl-1-piperazinyl, 4-Formy1-1-piperazinyl, 4-Acety1-1 r piperazinyl, 4-Propiony1-1-piperazinyl, '4-Methoxycarbony1-1-piperazinyl', 4-Ethoxycarbony1-1-piperazinyl, 2-pyrrolidinyl, 3_Py r i <olidinyl-, 2-piperidino, 3-piperidino , 4-piperidino, N-methyl-2-pyrrolidinyl, N-methyl-3-pyrrolidinyl, .N-methyl-4-piperidino, H-ethyl-4-piperidino, Ii-isopropyl-4-piperidino- , H-formyl-4-piperidino, U-acetyl-4-piperidinoj ·, N-propionyl-4-piperidino, morpholino, thiomor-pholino, 1-oxido-4-thiomorpholino, 1,1-dioxide ^ -thiomor-pholino, imidazoline
ai -ai -
2-on-1-yl-,.2-Methyl-2-imidazolin-1-ylT, Imidazolidin-2-on-4-yl-, 2-Me thy 1-4^5-dihydr ο-imidazo 1-1-yl-, Imidazolin-2-on-4-yl-, Tetrahydrdfuran-2-yl-, 4~Methyl-2-piperazinyl-, 4-Ethyl-2-piperazinyl*-, .4-n-Piropy l-2-pipe:tfazinyl-, 1,4-Dimethyl-2-piperazinyl-, 1 ^-Diethyl^-piperazinyl-, 1-Ethyl-4-methyl-2-piperazinyl-, 1-Pyrrplyl-, 2-Pyrrolyl-, -3-Pyrrolyl-, I-Methyl-2-pyrroIyI-,',H-Ethyl-2-pyrrοIyI-, N-Methy 1-3-pyrroIyI-, Ii- Ethyl-3-pyrrolyl-, 2-Thienyl-, 3-Thienyl-, 2-Pyridyl-, 3-Pyridyl-, 4-Pyridyl-, 2-Pyrazin.yl-, 1-ImidazoIyI-, · 2-MetHyl-1-imidazoIyI-,'4-Methyl-1-imidazoIyI-, 2-Ethyl-1-imidazolyl-, '4-Ethy 1-1-imidazoIyI-, 2-Amino-5-pyridyl-, " 2-ϊ1ormylamino-5-pyridyl-, 2-Acetylamino-5-pyridyl-, 2-Propionylamino-5-pyridyl-, 2,6-Dichlor-4--pyridyl-,i 2-Chlor-6-amino-4-pyridyl-, 2-Chlor-6-morpholino-4-pyridyl-., ^,ö-Dichlor^-pyridyl-, ,2-Chlor-6-mo^pholino-3-pyridyl-, 1-Pyrazolyl-, 4-Methyl-i-pyrazolyl-, :3-Hydroxy-4-methyl-2-pyrazoIyI-, 5-0xazolyl-, 4-Methyl-5-oxazolyl-, 4-PyrazoIyI-, 3-imino-4-pyrazoIyI-, Λ-Γ\ .2.3-7-Triazolyl-, 1-/1.2.47TrXaZoIyI-, 2-Hydroxy-1-imidazoIyI-, 4-Hydroxy-1 -imidazoIyI-, 4-Methyl-i-imidaz'olyl-, 2-Imidazolyl-, Imidazolidin-2-on-l-yl-, 2-Pyrimidyl-, 5-Pyrimidyl-, 4-Pyrimidyl-, 5-Thiazolyl-, 2-Thiazolyl-, 2-Oxazolyl- oder Triazol-3-yl-gruppe in Betracht. , ; · ·' "2-on-1-yl, 2-methyl-2-imidazolin-1-yl T , imidazolidin-2-one-4-yl, 2-methyl-4-yl-dihydro-imidazo-1 1-yl, imidazolin-2-one-4-yl, tetrahydrodfuran-2-yl, 4-methyl-2-piperazinyl, 4-ethyl-2-piperazinyl * -, .4-n-piropyl 2-pipe: tfazinyl, 1,4-dimethyl-2-piperazinyl, 1'-diethyl-1-piperazinyl, 1-ethyl-4-methyl-2-piperazinyl, 1-pyrroleyl, 2-pyrrolyl, 3-pyrrolyl, 1-methyl-2-pyrrolyl, '', H-ethyl-2-pyrrorylo, N-methyl-1-pyrrolyl, 1-ethyl-3-pyrrolyl, 2-thienyl, 3-Thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrazinyl, 1-imidazolyl, 2-methyl-1-imidazolyl, 4-methyl-1-imidazolyl -, 2-ethyl-1-imidazolyl, '4-ethyl-1-1-imidazolyl, 2-amino-5-pyridyl, "2-yl- 1- amylamino-5-pyridyl, 2-acetylamino-5-pyridyl -, 2-Propionylamino-5-pyridyl, 2,6-dichloro-4 - pyridyl, i 2-chloro-6-amino-4-pyridyl, 2-chloro-6-morpholino-4-pyridyl. , ^, ö-dichloro-pyridyl,, 2-chloro-6-monophosphino-3-pyridyl, 1-pyrazolyl, 4-methyl-i-pyrazolyl,: 3-hydroxy-4-methyl- 2-pyrazolinyl, 5-oxazolyl, 4-methyl-5-oxaz olyl-, 4-PyrazoIyI-, 3-imino-4-pyrazoIyI-, Λ-Γ \ .2.3-7-triazolyl, 1- / 1.2.47TrXaZoIyI-, 2-hydroxy-1-imidazoIyI-, 4-hydroxy 1-imidazolinyl, 4-methyl-1-imidazolyl, 2-imidazolyl, imidazolidin-2-one-1-yl, 2-pyrimidyl, 5-pyrimidyl, 4-pyrimidyl, 5-thiazolyl , 2-Thiazolyl, 2-oxazolyl or triazol-3-yl group into consideration. ,; · · '"
Bevorzugte Verbindungen der obigen allgemeinen Pormel I sind 3"edoch diejenigen, in denen . . . " Preferred compounds of the above general formula I are 3 "but those in which..."
X die Iminogruppe, ein Sauerstoff- oder Schwefelatom, R1 eine über ein Stickstoffatom gebundene Pyrrolid'inyl-, Piperidino-, 1-Hexahydroazepinyl-, Mprpholino-, Thiomorpholino-, 1-Oxidothiomorpholino-, 1,1-Dioxidothiomorpholino-, 1-Piperazinyl-, 4-Methyl-i-piperazihyl-, 4-Acetyl-1-piperazinylT 4-Carbäthoxy-1-piperazinyl-, .1-ImidazoIyI-, 1-Pyraz.olyl-, 1-/Ί.2.47TrIaZoIyI-, Imidazolidin-2-on-l-yl- oder 3-Hydroxy-2-pyrazoIy!gruppe oder eine über ein Kohlenstoffatom gebundene Piperidino-, N-Acetyl-piperidino-, Puryl-, Thienyl-, Pyrrolyl-,X is the imino group, an oxygen or sulfur atom, R 1 is a pyrrolidinyl, piperidino, 1-hexahydroazepinyl, mprpholino, thiomorpholino, 1-oxidothiomorpholino, 1,1-dioxothiomorpholino, 1 bonded via a nitrogen atom, 1 Piperazinyl, 4-methyl-1-piperazihyl, 4-acetyl-1-piperazinyl, T 4-carbethoxy-1-piperazinyl, .1-imidazolyl, 1-pyrazolyl, 1-, 2-4-7-triazole, Imidazolidin-2-on-1-yl or 3-hydroxy-2-pyrazolyl group or a piperidino, N-acetyl-piperidino, puryl, thienyl, pyrrolyl, bonded via a carbon atom,
- 13; * .- ' 66 648/12- 13; * .- '66 648/12
Pyridyl-, Amino-pyridyl-, Acetylamino-pyridyl-, Pyrimidyl-, Pyrazinyl-, Qxazolyl-, Dihalogen-pyridyl- oder Halogen-morpholino-pyridylgruppe,^wobei alle vorstehend erwähnten Reste im Kohlenstoffgerüst durch eine·Methylgruppe substituiert sein können und .„ --" · . _ . ~Pyridyl, amino-pyridyl, acetylamino-pyridyl, pyrimidyl, pyrazinyl, qxazolyl, dihalo-pyridyl or halo-morpholino-pyridyl group, wherein all the above-mentioned radicals in the carbon skeleton may be substituted by a methyl group, and. "-" ·. _. ~
Rp ein Wasserstoffatom oder eine Methylgruppe in 5-Stellung bedeutenο . -Rp represents a hydrogen atom or a methyl group in the 5-position o. -
Besonders bevorzugte Verbindungen der obigen allgemeinen Formel I sind jedoch diejenigen, in denen ; ... Σ ein Sauerstoffatom oder die Iminogruppe,. R-ydie 1-Pyrrolidinyl-, 1-Imidazolyl-r, 2-Puryl-, 2-Thienyl-., 1-Piperazinyl-, 4-Methyl-i-piperazinyl-, 4-Carbäthoxy-1 -" pipe,razinyl-, 4-Morpholino-, 4-Thiomorpholino-, 1-r0xido-4-.thiomorpholino- und 4-Pyridylgruppe und . - v Rg in 5-Stelluhg die Methylgruppe bedeuten·However, particularly preferred compounds of the above general formula I are those in which; ... Σ an oxygen atom or the imino group ,. R- y represents the 1-pyrrolidinyl, 1-imidazolyl-r, 2-puryl, 2-thienyl, 1-piperazinyl, 4-methyl-1-piperazinyl, 4-carbethoxy-1-pipe, razinyl , 4-morpholino, 4-thiomorpholino, 1-r0xido-4-thiomorpholino and 4-pyridyl groups and - v Rg in 5-Stelluhg mean the methyl group
. - fc - , - fc -
Die neuen Verbindungen der allgemeinen lOrmel I, deren optisch aktiven Antipoden und deren Säureadditionssalze, insbe-.sondere deren physiologisch verträgliche Säureadditionssalze mit'anorganischen oder organischen Säuren weisen'wertvolle pharmakologische Eigenschaften auf, insbesondere cardiovasculäre Wirkungen, nämlich eine cardiotonische und/oder blutdrucksenkende, 'und eine antithrombotische Wirkung»The novel compounds of general formula I, their optically active antipodes and their acid addition salts, in particular their physiologically acceptable acid addition salts with inorganic or organic acids, have valuable pharmacological properties, in particular cardiovascular effects, namely a cardiotonic and / or hypotensive, and an antithrombotic effect »
Beispielsweise vmrden die VerbindungenFor example, the connections are different
A= 5-Methyl-6-/5-(1-imidazolyl)-benzos:azol-5-yl7-4,5-dihydro-3(2H)-pyridazinon,A = 5-methyl-6- / 5- (1-imidazolyl) -benzo: azol-5-yl7-4,5-dihydro-3 (2H) -pyridazinone,
B = 5-Methy 1-6-/2-(-1 -piperazinyl)-benzo2azol-6-y]t7-4, 5-dihydro· '3 (2H)-pyridazinon, B = 5-Methyl-1-6 / 2 - (- 1 -piperazinyl) -benzo2azol-6-y] t 7-4, 5-dihydro · '3 (2H) -pyridazinone,
C = 5-(Methy 1-6-/2-(4-carbäthoxy-1-piperazinyl)-benzoxazol-6-yl/-4,5-dihydro-3(2H)-pyridazinon,C = 5- (methyl 1-6- / 2- (4-carbethoxy-1-piperazinyl) benzoxazol-6-yl / -4,5-dihydro-3 (2H) -pyridazinone,
D =.5-Methyl-6-/2-(i-pyrrolidinyl)-benzimidazol-5-yl7-4,5-dihydro-3(2H)-pyridazinon,D = .5-methyl-6- / 2- (i-pyrrolidinyl) -benzimidazol-5-yl7-4,5-dihydro-3 (2H) -pyridazinone,
248248
E = 5-Methyl-6-[2-(4-thiomorpholino)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon undE = 5-methyl-6- [2- (4-thiomorpholino) -benzimidazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone;
F. = 5-Methyl-6-[2-(1-imidazolyl)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinonF. = 5-Methyl-6- [2- (1-imidazolyl) -benzimidazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
auf ihre biologischen Eigenschaften wie folgt untersucht:examined for their biological properties as follows:
1. Bestimmung der Thrombozytenaggregation nach Born und Cross (J. Physiol. 170, 397 (1964)):1. Determination of Born and Cross Platelet Aggregation (J. Physiol 170, 397 (1964)):
Die Thrombozytenaggregation wurde in plättchenreichem Plasma gesunder Versuchspersonen gemessen. Hierbei wurde der Verlauf der Abnahme der optischen Dichte nach Zugabe von handelsüblichem Collagen der'Firma Sigma, St. Louis/USA, welches 1 mg Collagen-Fibrillen pro ml enthält, photometrisch gemessen und registriert. Aus dem Neigungswinkel der Dichtekurve wurde auf die Aggregationsgeschwindigkeit (Vmax) geschlossen. Der Punkt der Kurve, bei dem die größte Lichtdurchlässigkeit vorlag, diente zur Berechnung der "optical density" (O.D.). Zur maximalen Aggregationsauslösung werden ca. 0,01 ml der Collagenlösung zu 1 ml plättchenreichem Plasma gegeben. . .Platelet aggregation was measured in platelet-rich plasma of healthy volunteers. In this case, the course of the decrease in the optical density after the addition of commercially available collagen from the company Sigma, St. Louis / USA, which contains 1 mg of collagen fibrils per ml, was measured photometrically and registered. From the inclination angle of the density curve was closed on the aggregation speed (Vmax). The point of the curve where the greatest light transmittance existed was used to calculate the "optical density" (O.D.). For maximum aggregation release, add about 0.01 ml of the collagen solution to 1 ml of platelet-rich plasma. , ,
Die nachfolgende Tabelle enthält den gefundenen Wert: Tabelle IThe following table contains the found value: Table I
BB
2. Bestimmung der blutdrucksenkenden und positiv inotropen Wirkung an der narkotisierten Katze: 2. Determination of hypotensive and positive inotropic effect on the anesthetized cat:
Die Untersuchungen wurden an Katzen durchgeführt, die mit Pentobarbital-Natrium (40 mg/kg i.p.) narkotisiert waren. Die Tiere atmeten spontan. Der arterielle Blutdruck wurde in der Aorta abdominalis mit einem Statham-Druckwandler (P 23 Dc) gemessen. Für die Erfassung der positiv inotropen Wirkung wurde mit einem Kathetertipmanometer (Milliar PC-350 A) der Druck in der linken Herzkammer gemessen. Daraus wurde der Kontraktilitätsparameter dp/dt__„ mittelsThe studies were performed in cats that were anesthetized with pentobarbital sodium (40 mg / kg i.p.). The animals breathed spontaneously. Arterial blood pressure was measured in the abdominal aorta with a Statham pressure transducer (P 23 Dc). To measure the positive inotropic effect, the pressure in the left ventricle was measured with a catheter tip manometer (one billion PC-350 A). From this, the contractility parameter dp / dt__ "by means of
iHaXiHaX
eines Analogdifferenzierers gewonnen. Die zu untersuchende Substanz wurden in eine Vena femoralis injiziert. Als Lösungsmittel diente Polydiol 200. Die Substanz wurde an 3 Katzen geprüft, Dosis 0,1 i.v..an analog differentiator won. The substance to be tested was injected into a femoral vein. The solvent used was polydiol 200. The substance was tested on 3 cats, dose 0.1 i.v ..
Die nachfolgende Tabelle enthält die Mittelwerte:The following table contains the mean values:
In diesem Zusammenhang sei darauf hingewiesen, daß bei den biologischen Untersuchungen keine toxischen Nebenwirkungen der Substanzen beobachtet wurden.In this context, it should be noted that no toxic side effects of the substances were observed in the biological studies.
- "16 - 66 648/12- "16 - 66 648/12
Aufgrund ihrer pharmakologischen Eigenschaften, .eignen sich ^ die erfindungsgemaß erhge st eilt en.'Verbindungen der allgemeinen Formel I und deren optisch aktive Antipoden sowie deren physiologisch verträgliche Säureadditionssalze.mit anorganischen oder organischen'Säuren zur Behandlung der chronischen-Herzinsuffizienz oder der Angina Pectoris und/oder zur Prophylaxe arterieller.Thromboembolien und arterieller Verschlußkrankheiten. ./ " ' _. ' · ·'On the basis of their pharmacological properties, the compounds of the general formula I and their optically active antipodes and their physiologically tolerated acid addition salts with organic or organic acids for the treatment of chronic heart failure or angina pectoris and / or for the prophylaxis of arterial.Thromboembolien and arterial occlusive diseases. ./ '' _. '· ·'
Hierzu lassen sich die neuen Verbindungen, gegebenenfalls in Kombination, mit anderen Wirksubstanzen,, in die üblichen phar-.mazeutischen Anwendungsformen.wie Tabletten, Dragees, Pulver, Suspensionen,-Suppositorien oder.Ampullen einarbeiten. Die Einzeldosis -beträgt hierbei beim Erwachsenen Λ - 4 x täglich bei intravenöser Applikation 1-50 mg, vorzugsweise 2 bis 40 mg,^ und bei oraler Application 5 - 150 mg, vorzugsweise 5 100 mg. . - ' ' . _ ' .For this purpose, the new compounds, optionally in combination, with other active ingredients ,, in the usual phar-.mazeutischen Anwendungsformen.wie teach such as tablets, dragees, powders, suspensions, suppositories or.Ampullen. The single dose is in this case in adults Λ - 4 x daily with intravenous administration 1-50 mg, preferably 2 to 40 mg, ^ and in oral application 5 - 150 mg, preferably 5 100 mg. , - ''. _ '.
Ausführungsbeispiel· ' . ' -' . Embodiment . '-'.
Die nachfolgenden Beispiele sol·l·en die Erfindung näher erläutern: . - · . .The following examples are intended to explain the invention in more detail: - ·. ,
5-Methyl-6-[2-(2,6-dichlor-4-pyridyl)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon.5-Methyl-6- [2- (2,6-dichloro-4-pyridyl) -benzimidazole-5-yl] -4,5-dihydro-3 (2H) -pyridazinone.
4,0 g (10,2 mMol) N-[2-Amino-4-(5-methyl-4,5-dihydro-3(2H)-pyridazinon-6-yl)-phenyl]-2,6-dichlor-pyridin-4-carbonsäure- amid werden in 50 ml Eisessig gelöst, 5 Minuten lang auf 1000C erhitzt, dann auf Raumtemperatur abgekühlt, das ausgefallene Produkt abgesaugt, mit Diethylether gewaschen und an der Luft getrocknet4.0 g (10.2 mmol) of N- [2-amino-4- (5-methyl-4,5-dihydro-3 (2H) -pyridazinone-6-yl) -phenyl] -2,6-dichloro -pyridine-4-carboxylic acid amide are dissolved in 50 ml of glacial acetic acid, heated for 5 minutes at 100 0 C, then cooled to room temperature, the precipitated product is filtered off, washed with diethyl ether and dried in air
Ausbeute: 86 % der Theorie, Schmelzpunkt: 260-2640C C17H13Cl2N5O (374,2) Ber. : C 54,56 H 3,50 N Gef.: 54,30 . 3,67Yield: 86% of theory, Melting point: 260-264 0 CC 17 H 13 Cl 2 N 5 O (374.2) Calcd. : C 54.56 H 3.50 N Gef .: 54.30. 3.67
5-Methy1-6-[2-(2-pyrazinyl)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methy1-6- [2- (2-pyrazinyl) -benzimidazole-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Amino-4-(5-methyl-4,5-dihydro-3(2H)-pyridazinon-6-yl)-phenyl]-pyrazin-2-carbonsäureamid analog Beispiel 1.Prepared from N- [2-amino-4- (5-methyl-4,5-dihydro-3 (2H) -pyridazinone-6-yl) -phenyl] -pyrazine-2-carboxamide analogously to Example 1.
Ausbeute: 47,7 % der Theorie, Schmelzpunkt: > 3000CYield: 47.7% of theory, melting point:> 300 ° C.
Ber.: C 62,74 H 4,61 N 27,44 Gef.: 63,00 4,76 27,62Calc .: C 62.74 H 4.61 N 27.44 F .: 63.00 4.76 27.62
-is- ' 248 36-is- '248 36
6- [2-(2-Furyl)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon6- [2- (2-Furyl) -benzimidazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Amino-4-(4,5-dihydro-3(2H)-pyridazin-5 on-6-yl)-phenyl]-furan-2-carbonsäureamid analog Beispiel 1. Ausbeute: 36,7 % der Theorie, Schmelzpunkt: > 3000CPrepared from N- [2-amino-4- (4,5-dihydro-3 (2H) -pyridazine-5-on-6-yl) -phenyl] -furan-2-carboxylic acid amide analogous to Example 1. Yield: 36.7 % of theory, melting point:> 300 0 C
Ber. : C 64,27 H 4,32 N 19,99 Gef.: 63,96 4,43 19,69Ber. : C 64.27 H 4.32 N 19.99 F .: 63.96 4.43 19.69
6-[2-(2-Thienyl)-benzimidazol-5-yl]-4,5-dihydro-3 (2H)-pyridazinon6- [2- (2-Thienyl) -benzimidazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Amino-4-(4,5-dihydro-3(2H)-pyridazinon-6-yl)-phenyl]-thiophen-2-carbonsäureamid analog Beispiel l.Prepared from N- [2-amino-4- (4,5-dihydro-3 (2H) -pyridazinone-6-yl) -phenyl] -thiophene-2-carboxamide analogously to Example 1.
Ausbeute: 29,8 % der Theorie,Yield: 29.8% of theory,
Schmelzpunkt: 170-1740CMelting point: 170-174 0 C
Ber.: C 60,78 H 4,08 N 18,90 S 10,81 Gef.: 60,34 4,34 18,77 10,62Calc .: C, 60.78; H, 4.08; N, 18.90, S, 10.81; F: 60.34, 4.34, 18.77, 10.62
5-Methyl-6-[2-(3-thienyl)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (3-thienyl) benzimidazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Amino-4-(5-methyl-4,5-dihydro-3(2H) -Prepared from N- [2-amino-4- (5-methyl-4,5-dihydro-3 (2H) -]
pyridazinon-6-yl)-phenyl]-thiophen-3-carbonsäureamid analog Beispiel 1.pyridazinone-6-yl) -phenyl] -thiophene-3-carboxamide analogously to Example 1.
Ausbeute: 71.% der Theorie, Schmelzpunkt: 184-1860CYield: 71% of theory, Melting point: 184-186 0 C.
Ber.: C 61,91 H 4,55 N 18,05 S 10,33 Gef. : 62,22 4,71 18,14 10,66Calc .: C, 61.91, H, 4.55, N, 18.05; S, 10.33; V: 62.22, 4.71, 18, 14, 10.66
6-[2-(3-Thienyl)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon6- [2- (3-thienyl) benzimidazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Amino-4-(4,5-dihydro-3(2H)-pyridazinon-6-yl)-phenyl]-thiophen-3-carbonsäureamid analog BeispielPrepared from N- [2-amino-4- (4,5-dihydro-3 (2H) -pyridazinone-6-yl) -phenyl] -thiophene-3-carboxamide analogously to Example
Ausbeute: 73 % der Theorie,Yield: 73% of theory,
Schmelzpunkt: 176-1780C Ber.: C 60,78 H 4,08 N 18,90 S 10,82 Gef.: 60,55 4,32 18,96 10,64Melting point: 176-178 0 C Calc .: C 60.78 H 4.08 N 18.90 S 10.82 Found .: 60.55 4.32 18.96 10.64
5-Methyl-6-[2-(2-furyl)-benzimidazol-5-yl]-4,5-dihydro-3(2H) pyridazinon5-methyl-6- [2- (2-furyl) -benzimidazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Amino-4-(5-methyl-4,5-dihydro-3(2H)-pyridazinon-6-yl)-phenyl]-furan-2-carbonsäureamid analogPrepared from N- [2-amino-4- (5-methyl-4,5-dihydro-3 (2H) -pyridazinone-6-yl) -phenyl] -furan-2-carboxamide analog
Ausbeute: 24,7 % der Theorie,Yield: 24.7% of theory,
Schmelzpunkt: 264-266°C Ber.: C 65,30 H 4,80 N 19,04 Gef.: 65,62 4,95 19,34Melting point: 264-266 ° C Calc .: C 65.30 H 4.80 N 19.04 Found: 65.62 4.95 19.34
- 248- 248
5-Methyl-6-[2-(3-pyridyl)-benzoxazol-5-yl]-4,5-dihydro-3(2H) pyridazinon5-Methyl-6- [2- (3-pyridyl) -benzoxazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
2 g (6,0 mMol) N-[2-Hydroxy-5-(5-methyl-4,5-dihydro-3(2H) pyridazinon-6-yl)-phenyl!-pyridin-3-carbonsäureamid werden in 40 ml Eisessig suspendiert und 20 Stunden lang in einer Stahlbombe mit Glaseinsatz auf 1500C erhitzt. Danach wird die Essigsäure abdestilliert, der Rückstand mit Wasser verrührt, dann abgesaugt und getrocknet. Die weitere Reinigung erfolgt durch Chromatographie über Kieselgel (Elutionsmittel: Dichlorraethan + 6 % Ethanol)2 g (6.0 mmol) of N- [2-hydroxy-5- (5-methyl-4,5-dihydro-3 (2H) pyridazinone-6-yl) -phenyl! -Pyridine-3-carboxamide are added in 40 glacial acetic acid and heated for 20 hours in a steel bomb with glass insert to 150 0 C. Thereafter, the acetic acid is distilled off, the residue is stirred with water, then filtered off with suction and dried. Further purification is carried out by chromatography over silica gel (eluent: dichloroethane + 6% ethanol).
Ausbeute: 38,3 % der Theorie, Schmelzpunkt: 223-225°C Ber.: C 66,66 H 4,61 N 18,29 Gef.: 66,53 4,35 18,20 Yield: 38.3% of theory, m.p .: 223-225 ° C Calc .: C 66.66 H 4.61 N 18.29 V: 66.53 4.35 18.20
5-Methyl-6-[2-(4-pyridyl)-benzoxazol-5-yl]-4,5-dihydro-3(2H) pyridazinon5-methyl-6- [2- (4-pyridyl) -benzoxazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-5-(5-methyl-4,5-dihydro-3(2H)-pyridazinon-6-yl)-phenyl]-pyridin-4-carbonsäureamid analogPrepared from N- [2-Hydroxy-5- (5-methyl-4,5-dihydro-3 (2H) -pyridazinon-6-yl) -phenyl] -pyridine-4-carboxamide analog
Ausbeute: 39,9 % der Theorie,Yield: 39.9% of theory,
Schmelzpunkt: 238-2400CMelting point: 238-240 0 C
Ber.: C 66,66 H 4,61 N 18,29Calc .: C 66.66 H 4.61 N 18.29
Gef.: 67,00 4,73 18,65Gef .: 67.00 4.73 18.65
- 21 - 2- 21 - 2
5-Methyl-6-[2-(2-acetamino-5-pyridyl)-benzoxazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (2-acetamino-5-pyridyl) benzoxazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-5-(5-methyl-4,5-dihydro-3(2H) pyridazinon-6-yl)-phenyl]-2-acetamino-pyridin-5-carbonsäure- amid analog Beispiel Ausbeute: 20,7 % der Theorie, Schmelzpunkt: 299-3000C Ber.: C 62,80 H 4,72 N 19,27 Gef.: 62,90 5,01 18,98Prepared from N- [2-hydroxy-5- (5-methyl-4,5-dihydro-3 (2H) -pyridazinone-6-yl) -phenyl] -2-acetaminopyridine-5-carboxylic acid amide analogously to Example Yield : 20.7% of theory, melting point: 299-300 0 C Calc .: C 62.80 H 4.72 N 19.27 Found .: 62.90 5.01 18.98
5-Methyl-6-[2-(2-furyl)-benzoxazol-5-yl]-4,5-dihydro-3(2H) pyridazinon5-Methyl-6- [2- (2-furyl) -benzoxazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-5-(5-methyl-4,5-dihydro-3(2H) pyridazinon-6-yl)-phenyl]-furan-2-carbonsäureamid analog Prepared from N- [2-Hydroxy-5- (5-methyl-4,5-dihydro-3 (2H) pyridazinone-6-yl) -phenyl] -furan-2-carboxamide analog
Ausbeute: 22,2 % der Theorie, Schmelzpunkt: 204-2050C Ber.: C 65,08 H 4,44 N 14,23 Gef.: 64,79 4,44 14,27Yield: 22.2% of theory, Melting point: 204-205 0 C Calc .: C 65.08 H 4.44 N 14.23 Found .: 64.79 4.44 14.27
5-Methyl-6-[2-(2-thienyl)-benzoxazol-5-yl]-4,5-dihydro-3(2H) pyridazinon5-Methyl-6- [2- (2-thienyl) -benzoxazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-5-(5-methyl-4,5-dihydro-3(2H) -Prepared from N- [2-hydroxy-5- (5-methyl-4,5-dihydro-3 (2H) -]
22 *.*0 322 *. * 0 3
pyridazinon-6-yl)-phenyl]-thiophen-2-cafbonsäureamid analog Beispiel 8.pyridazinone-6-yl) -phenyl] -thiophene-2-cocottonamide analogously to Example 8.
Ausbeute: 50,5 % der Theorie, Schmelzpunkt: 214-215°C Ber.: C 61,71 H 4,21 N 13,50 S 10,30 Gef.: ^ 61,46 4,25 13,31 10,37Yield: 50.5% of theory, melting point: 214-215 ° C calc .: C 61.71 H 4,21 N 13,50 S 10,30 V: 61.46 4.25 13.31 10, 37
5-Methyl-6-[2-(3-thienyl)-benzoxazol-5-yl]-4,5-dihydro-3(2H) pyridazinon5-methyl-6- [2- (3-thienyl) -benzoxazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-5-(5-methyl-4,5-dihydro-3(2H)-pyridazinon-6-yl)-phenyl]-thiophen-3-carbonsäureamid analogPrepared from N- [2-Hydroxy-5- (5-methyl-4,5-dihydro-3 (2H) -pyridazinon-6-yl) -phenyl] -thiophene-3-carboxamide analog
Ausbeute: 22,3 % der Theorie, Schmelzpunkt: 222-2240C Ber.: C 61,71 H 4,21 N 13,50 S 10,30 Gef.: 61,37 4,12 13,50 10,60Yield: 22.3% of theory, Melting point: 222-224 0 C Calc .: C 61.71 H 4.21 N 13.50 S 10.30 Found .: 61.37 4.12 13.50 10.60
6-[2-(4-Methyl-oxazol-5-yl)-benzoxazol-5-yl]-4,5-dihydro-3 (2H)-pyridazinon6- [2- (4-Methyl-oxazol-5-yl) -benzoxazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-5-(4,5-dihydro-3(2H)-pyridazinon-6-yl)-phenyl]-4-methyl-oxazol-5-carbonsäureamid analogPrepared from N- [2-hydroxy-5- (4,5-dihydro-3 (2H) -pyridazinone-6-yl) -phenyl] -4-methyl-oxazole-5-carboxylic acid amide analog
Ausbeute: 12,7 % der Theorie, Schmelzpunkt: 238-24O0C Ber.: C 60,80 H 4,08 N 18,91 Gef.: 60,98 4,18 18,90Yield: 12.7% of theory, melting point: 238-24O 0 C calc .: C 60.80 H 4.08 N 18.91 Gef .: 60.98 4.18 18.90
- 23 - 248- 23 - 248
6- [2-(3-Thienyl)-benzoxazol-5-yl]-4,5-dihydro-3(2H)-pyrida zinon6- [2- (3-Thienyl) -benzoxazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-5-(4,5-dihydro-3(2H)-pyridazin-5 on-6-yl)-phenyl]-thiophen-3-carbonsäureamid analog Beispiel 8.Prepared from N- [2-hydroxy-5- (4,5-dihydro-3 (2H) -pyridazin-5-on-6-yl) -phenyl] -thiophene-3-carboxamide analogously to Example 8.
Ausbeute: 15 % der Theorie, Schmelzpunkt: 262-2630CYield: 15% of theory, Melting point: 262-263 0 C.
Ber.: . C 60,60 H 3,73 N 14,14 S 10,79 Gef.: 60,56 3,54 14,00 10,93Ber .:. C 60.60 H 3.73 N 14.14 S 10.79 Vig .: 60.56 3.54 14.00 10.93
5-Methyl-6-[2-(2-thienyl)-benzthiazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (2-thienyl) benzothiazole-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
1,7 g (4,9 mMol) N-[2-Mercapto-5-(5-methyl-4,5-dihydro-3(2H) -J5 pyridazinon-6-yl)-phenyl]-thiophen-2-carbonsäureamid werden geschmolzen, bis keine Gasentwicklung mehr zu beobachten ist. Durch Säulenchromatographie über 200 g Kieselgel (EIutionsmittel: Dichlormethan + 5 % Ethanol) wird das so erhaltene Produkt gereinigt1.7 g (4.9 mmol) of N- [2-mercapto-5- (5-methyl-4,5-dihydro-3 (2H) -5-pyridazinone-6-yl) -phenyl] -thiophene-2 carboxylic acid amide are melted until no gas evolution is observed. By column chromatography over 200 g of silica gel (eluent: dichloromethane + 5% ethanol), the product thus obtained is purified
Ausbeute: 11 % der Theorie, Schmelzpunkt: 203-2040CYield: 11% of theory, Melting point: 203-204 0 C.
C16H13N3OS2 (327'4) C 16 H 13 N 3 OS 2 (327 ' 4)
Ber.: C 58,69 H 4,00 N Gef.: 58,33 4,12Calc .: C 58.69 H 4.00 N Gef .: 58.33 4.12
Beispiel 17Example 17
5-Methyl-6-[2-(2-furyl)-benzthiazol-5-yl]-4,5-dihydro-3(2H) pyridazinon5-methyl-6- [2- (2-furyl) -benzothiazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Mercapto-5-(5-methyl-4,5-dihydro-3(2H)-pyridazinon-6-yl]-furan-2-carbonsäureamid analog Beispiel 16, Ausbeute: 28 % der Theorie, Schmelzpunkt: 223-224°CPrepared from N- [2-mercapto-5- (5-methyl-4,5-dihydro-3 (2H) -pyridazinone-6-yl] -furan-2-carboxamide analogously to Example 16, yield: 28% of theory, Melting point: 223-224 ° C
Ber.: C 61,72 H 4,21 N 13,50 S 10,30 Gef.: - 61,90 4,21 13,40 10,43Calcd .: C 61.72 H 4,21 N 13,50 S 10,30 Found: - 61,90 4,21 13,40 10,43
5-Methyl-6-[2-(1-piperazinyl)-benzoxazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (1-piperazinyl) benzoxazole-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
1,5 g (5,4 mMol) 5-Methyl-6-(2-methylthio-benzoxazol-5-yl)-4,5-dihydro-3(2H)-pyridazinon werden mit 10 g Piperazin gemischt und 2 Stunden lang auf 1600C erhitzt. Danach wird das Reaktionsgemisch mit ca. 300 ml Wasser verrührt, das ungelöste Produkt abgesaugt und mit Wasser gewaschen. Die Reinigung erfolgt durch Säulenchromatographie (basisches Aluminiumoxid, Elutionsmittel: Methylenchlorid + 2 % Ethanol).1.5 g (5.4 mmol) of 5-methyl-6- (2-methylthio-benzoxazol-5-yl) -4,5-dihydro-3 (2H) -pyridazinone are mixed with 10 g of piperazine and stirred for 2 hours heated to 160 0 C. Thereafter, the reaction mixture is stirred with about 300 ml of water, the undissolved product is filtered off with suction and washed with water. The purification is carried out by column chromatography (basic alumina, eluent: methylene chloride + 2% ethanol).
Ausbeute: 44,4 % de'r Theorie, Schmelzpunkt: 215-216°CYield: 44.4% of theory, m.p .: 215-216 ° C
C16H19N5°2 (313,4) C 16 H 19 N 5 ° 2 (313.4)
Ber.: C 61,33 H 6,11 N 22,35Calc .: C 61.33 H 6.11 N 22.35
Gef. : 61,15 6,12 ' 22,00Gef.: 61.15 6.12 '22.00
Beispiel 19Example 19
5-Methyl-6-[2-(1-pyrrolidinyl)-benzoxazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (1-pyrrolidinyl) -benzoxazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 5-Methyl-6-(2-methylthio-benzoxazol-5-yl)-4,5-dihydro-3(2H)-pyridazinon und Pyrrolidin analog Beispiel 18.Prepared from 5-methyl-6- (2-methylthio-benzoxazol-5-yl) -4,5-dihydro-3 (2H) -pyridazinone and pyrrolidine analogously to Example 18.
Ausbeute: 59,4 % der Theorie, Schmelzpunkt: 230-2310CYield: 59.4% of theory, Melting point: 230-231 0 C.
Ber.: C 64,41 H 6,08 N 18,78 Gef. : 64,70 6,16 18,86Calc .: C 64.41 H 6.08 N 18.78 Vessel: 64.70 6.16 18.86
5-Methyl-6-[2-(1-imidazolyl)-benzoxazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (1-imidazolyl) benzoxazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 5-Methyl-6-(2-methylthio-benzoxazol-5-yl)-4,5-dihydro-3(2H)-pyridazinon und Imidazol analog BeispielPrepared from 5-methyl-6- (2-methylthio-benzoxazol-5-yl) -4,5-dihydro-3 (2H) -pyridazinone and imidazole analogously to Example
Ausbeute: 31,4 % der Theorie,Yield: 31.4% of theory,
Schmelzpunkt: 236-238°CMelting point: 236-238 ° C
Ber.: C 61,01 H 4,44 N 23,72 Gef.: 60,76 4,62 24,01Calc .: C 61.01 H 4.44 N 23.72 V .: 60.76 4.62 24.01
5-Methyl-6- [2-(4-methyl-l-piperazinyl)-benzoxazol-5-yl] -4, 5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (4-methyl-1-piperazinyl) -benzoxazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 5-Methyl-6-(2-methylthio-benzoxazol-5-yl)-Prepared from 5-methyl-6- (2-methylthio-benzoxazol-5-yl) -
2 482 48
4,5-dihydro-3(2H)-pyridazinon und 1-Methyl-piperazin analog Beispiel 18.4,5-dihydro-3 (2H) -pyridazinone and 1-methyl-piperazine analogously to Example 18.
Ausbeute: 58,8 % der Theorie, Schmelzpunkt: 230-2310CYield: 58.8% of theory, Melting point: 230-231 0 C.
Ber.: C 62,37 H 6,47 ' N 21,39 Gef.: 62,56 6,53 21,44Calc .: C 62.37 H 6.47 'N 21.39 F .: 62.56 6.53 21,44
5-Methyl-6- [2- (2-methyl-l-imidazolyl).-benzoxazol-5-yl] -4, 5-dihydro-3(2H)-pyridazinon5-methyl-6- [2- (2-methyl-1-imidazolyl) -benzoxazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 5-Methyl-6-(2-methylthio-benzoxazol-5-yl)-4,5-dihydro-3(2H)-pyridazinon und 2-Methyl-imidazol in Dimethylsulfoxid durch 3-stündiges Erhitzen auf 1500C analog Beispiel 18Prepared from 5-methyl-6- (2-methylthio-benzoxazol-5-yl) -4,5-dihydro-3 (2H) -pyridazinone and 2-methyl-imidazole in dimethyl sulfoxide by heating for 3 hours at 150 0 C analog Example 18
Ausbeute: 18,8 % der Theorie, Schmelzpunkt: 214-2160CYield: 18.8% of theory, Melting point: 214-216 0 C.
Ber.: C 62,13 H 4,89 N 22,64 Gef.: 62,48 4,87 22,82Calc .: C 62.13 H 4.89 N 22.64 F .: 62.48 4.87 22.82
6-[2-(2-Methyl-l-imidazolyl)-benzoxazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon6- [2- (2-methyl-l-imidazolyl) benzoxazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 6-(2-Methylthio-benzoxazol-5-yl)-4,5-dihydro-3(2H)-pyridazinon und 2-Methyl-imidazol analog Beispiel 18.Prepared from 6- (2-methylthio-benzoxazol-5-yl) -4,5-dihydro-3 (2H) -pyridazinone and 2-methyl-imidazole analogously to Example 18.
Ausbeute: 54,2 % der Theorie, Schmelzpunkt: 242-243°CYield: 54.2% of theory, melting point: 242-243 ° C
Ber.: C 61,01 H 4,44 N 23,72 Gef. : 61,00 4,38 23,78Calc .: C 61.01 H 4.44 N 23.72 Vessel: 61.00 4.38 23.78
- 27 - 248 36 - 27 - 248 36
5-Methyl-6-[2-(4-methyl-l-pyrazolyl)-benzoxazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (4-methyl-l-pyrazolyl) benzoxazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 5-Methyl-6-(2-methylthio-benzoxazol-5-yl)-4,5-dihydro-3(2H)-pyridazinon und 4-Methyl-pyrazol analog Beispiel 18.Prepared from 5-methyl-6- (2-methylthio-benzoxazol-5-yl) -4,5-dihydro-3 (2H) -pyridazinone and 4-methyl-pyrazole analogously to Example 18.
Ausbeute: 16,6 % der Theorie, -Schmelzpunkt: 255-2570CYield: 16.6% of theory, -Schmelzpunkt: 255-257 0 C.
Ber.: C 62,13 H 4,89 N 22,64 Gef.: 61,90 5,00 22,58Calc .: C 62.13 H 4.89 N 22.64 F .: 61.90 5.00 22.58
6-[2-(N-Acetyl-4-piperidino)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon-hydrochlorid6- [2- (N-acetyl-4-piperidino) -benzimidazole-5-yl] -4, 5-dihydro-3 (2H) -pyridazinone hydrochloride
450 mg 6- [2-(4-Piperidino)-benzimidazol-5-yl]-4,5-dihydro-3'(2H) -pyridazinon werden in 50 ml Essigester und 15 ml Eisessig suspendiert. Hierzu gibt man 15 ml Acetanhydrid und erhitzt 2 Stunden am Rückfluß. Das Lösungsmittel wird entfernt und der Rückstand in Äther/Aceton verrieben. Anschliessend wird kurz mit Wasser erhitzt und nach Entfernen des Wassers der erhaltene Rückstand in Äthanol gelöst, mit Aktivkohle versetzt und abfiltriert. Beim Versetzen des FiI-trats mit ätherischer Salzsäure erhält man das gewünschte Produkt.450 mg of 6- [2- (4-piperidino) benzimidazol-5-yl] -4,5-dihydro-3 '(2H) -pyridazinone are suspended in 50 ml of ethyl acetate and 15 ml of glacial acetic acid. To this is added 15 ml of acetic anhydride and heated for 2 hours at reflux. The solvent is removed and the residue triturated in ether / acetone. The mixture is then heated briefly with water and dissolved after removal of the water, the residue obtained in ethanol, treated with activated charcoal and filtered off. Upon addition of the filtrate with ethereal hydrochloric acid, the desired product is obtained.
Ausbeute: 210 mg (37 % der Theorie), Schmelzpunkt: ab 2370C (Aceton).Yield: 210 mg (37% of theory), melting point: from 237 ° C. (acetone).
£. *+ \j OC Beispiel 26 £. * + \ j OC Example 26
5-Methyl-6-[2-(N-acetyl-4-piperidino)-benzimidazol-5-yl] 4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (N-acetyl-4-piperidino) -benzimidazol-5-yl] 4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 5-Methyl-6-[2-(4-piperidino)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon und Acetanhydrid analog Beispiel 25.Prepared from 5-methyl-6- [2- (4-piperidino) benzimidazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone and acetic anhydride analogously to Example 25.
Ausbeute: 16 % der Theorie, Schmelzpunkt: 245-2480CYield: 16% of theory, Melting point: 245-248 0 C.
Ber.: C 64,57 H 6,56 N 19,82 Gef. : 64,40 6,54 20,00Calc .: C 64.57 H 6.56 N 19.82 V: 64.40 6.54 20.00
6-[2-(4-Piperidino)-benzimidazol-5-yl]-4,5-dihydro-3(2H) pyridazinon-hydrochlorid6- [2- (4-piperidino) -benzimidazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone hydrochloride
3,6 g 6-[2-(2,6-Dichlor-4-pyridyl)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon werden in 100 ml Methanol 6 Stunden lang in einem Druckgefäß bei 500C und 5 bar Wasserstoff in Gegenwart von Palladium/Kohle hydriert. Anschliessend wird abfiltriert, das Filtra*t mit Ether versetzt und die ausgefallenen Kristalle abgesaugt. Das erhaltene Rohprodukt wird in Methanol gelöst, mit Aktivkohle versetzt und abfiltriert. Beim Versetzen des Filtrats mit etherischer Salzsäure' erhält man das gewünschte Produkt. Ausbeute: 2,05 g (61,4 % der Theorie), Schmelzpunkt: sintern ab 1000C3.6 g of 6- [2- (2,6-dichloro-4-pyridyl) -benzimidazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone are dissolved in 100 ml of methanol for 6 hours in a Hydrogenated pressure vessel at 50 0 C and 5 bar hydrogen in the presence of palladium / carbon. The mixture is then filtered off, the filter is admixed with ether and the precipitated crystals are filtered off with suction. The crude product obtained is dissolved in methanol, treated with activated charcoal and filtered off. Upon addition of the filtrate with ethereal hydrochloric acid, the desired product is obtained. Yield: 2.05 g (61.4% of theory), Melting point: sintering from 100 0 C.
6-[2-(2-Chlor-6-morpholino-4-pyridyl)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon6- [2- (2-chloro-6-morpholino-4-pyridyl) -benzimidazole-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
900 mg 6-[2-(2,6-Dichlor-4-pyridyl)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon werden in 15 ml Morpholin suspendiert und 1 Stunde auf 1000C erhitzt. Anschließend wird abgekühlt, abgesaugt, 1 χ mit Wasser ausgekocht und gut getrocknet. Danach wird der erhaltene Rückstand in Dimethylformamid gelöst, mit Aktivkohle versetzt, abfiltriert und das gewünschte Produkt durch Zusatz von Petrolether ausgefällt.900 mg of 6- [2- (2,6-dichloro-4-pyridyl) -benzimidazole-5-yl] -4,5-dihydro-3 (2H) -pyridazinone are suspended in 15 ml of morpholine and 1 hour at 100 0 C heated. It is then cooled, filtered off with suction, boiled 1 χ with water and dried well. Thereafter, the residue obtained is dissolved in dimethylformamide, mixed with activated charcoal, filtered off and the desired product is precipitated by the addition of petroleum ether.
Ausbeute: 300 mg (29,2 % der Theorie), Schmelzpunkt: über 3000CYield: 300 mg (29.2% of theory), melting point: above 300 ° C.
5-Methyl-6- [2-(2-pyridyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (2-pyridyl) -benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
6,5 g (20 mMol) N-[2-Hydroxy-4-(5-methyl-4,5-dihydro-3(2H)-pyridazinon-6-yl)-phenyl]-pyridin-2-carbonsäureamid (hergestellt aus Pyridin-2-carbonsäure, N,N'-Carbonyldiimidazol und 2-Hydroxy-4-(S-methyl-4,5-dihydro-3(2H)-pyridazinon-6-yl)-anilin) werden bei 1200C unter Rühren in 60 g Polyphosphorsäure eingetragen und 1 Stunde bei dieser Temperatur gehalten. Nach dem Abkühlen wird mit Eiswasser verdünnt, mit Ammoniak alkalisch gestellt und mit Methylenchlorid extrahiert. Der Extrakt wird mit Wasser gewaschen, mit Natriumsulfat getrocknet und das Lösungsdmittel im Vakuum abdestilliert. Der Rückstand wird mit Aceton aufgerührt, die anfallenden Kristalle abgesaugt und aus Isopropanol/Wasser umkristallisiert.6.5 g (20 mmol) of N- [2-hydroxy-4- (5-methyl-4,5-dihydro-3 (2H) -pyridazinone-6-yl) -phenyl] -pyridine-2-carboxylic acid amide (prepared from pyridine-2-carboxylic acid, N, N'-carbonyldiimidazole and 2-hydroxy-4- (S-methyl-4,5-dihydro-3 (2H) -pyridazinon-6-yl) -aniline) are at 120 0 C. added with stirring in 60 g of polyphosphoric acid and kept at this temperature for 1 hour. After cooling, it is diluted with ice-water, made alkaline with ammonia and extracted with methylene chloride. The extract is washed with water, dried with sodium sulfate and distilled off the solvent in vacuo. The residue is stirred with acetone, the resulting crystals are filtered off with suction and recrystallized from isopropanol / water.
- 30 - 248 3^2- 30 - 248 3 ^ 2
Ausbeute: 4,5 g (73,3 % der Theorie), Schmelzpunkt: 233°CYield: 4.5 g (73.3% of theory), m.p .: 233 ° C
Ber.: C 66,66 H 4,61 N 18,29Calc .: C 66.66 H 4.61 N 18.29
Gef.: 66,75 4,76 18,28Gef .: 66.75 4.76 18.28
5-Methyl-6-[2-(3-thienyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H) pyridazinon5-Methyl-6- [2- (3-thienyl) -benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
3,0 g (9,1 mMol) N-[2-(Hydroxy-4-(5-methyl-4,5-dihydro-3(2H) pyridazinon-6-yl]-thiophen-3-carbonsäureamid (hergestellt aus Thiophen-3-carbonsäure, N,N1-Carbonyldiimidazol und 2-Hydroxy-4-(5-methyl-4,5-dihydro-3(2H)-pyridazinon-6-yl)-anilin und 0,5 g p-Toluolsulfonsäure werden in 50 ml Eisessig gelöst und 8 Stunden zum Rückfluß erhitzt. Der Eisessig wird dann im Vakuum abdestilliert, der Rückstand mit Wasser und Diisopropyläther aufgerührt, abgesaugt und mit Wasser und dann mit Aceton gewaschen. Das Rohprodukt kristallisiert man aus Dioxan um.3.0 g (9.1 mmol) of N- [2- (hydroxy-4- (5-methyl-4,5-dihydro-3 (2H) -pyridazinone-6-yl] -thiophene-3-carboxylic acid amide (prepared from thiophene-3-carboxylic acid, N, N-carbonyldiimidazole and 1 2-hydroxy-4- (5-methyl-4,5-dihydro-3 (2H) -pyridazinone-6-yl) aniline and 0.5 g of p- Toluene sulfonic acid are dissolved in 50 ml of glacial acetic acid and heated to reflux for 8 hours The glacial acetic acid is then distilled off in vacuo, the residue stirred with water and diisopropyl ether, filtered with suction and washed with water and then with acetone The crude product is recrystallized from dioxane.
Ausbeute: 1,6 g (56,4 % der Theorie), Schmelzpunkt: 2350CYield: 1.6 g (56.4% of theory), m.p .: 235 ° C.
Ber.: C 61,72 H 4,21 N 13,50 S -10,30. Gef.: 61,45 4,45 13,52 10,14Calc .: C 61.72 H 4.21 N 13.50 S -10.30. Result: 61.45 4.45 13.52 10.14
5-Methyl-6-[2-(2-furyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H) pyridazinon5-methyl-6- [2- (2-furyl) -benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-4-(5-methyl-4,5-dihydro-3(2H) pyridazinon-6-yl)-phenyl]-furan-2-carbonsäureamid und Polyphosphorsäure analog Beispiel 29.Prepared from N- [2-hydroxy-4- (5-methyl-4,5-dihydro-3 (2H) -pyridazinone-6-yl) -phenyl] -furan-2-carboxamide and polyphosphoric acid analogously to Example 29.
- 31 -- 31 -
Ausbeute: 40 % der Theorie, Schmelzpunkt: 2090CYield: 40% of theory, melting point: 209 ° C.
Ber.: C 65,08 H 4,44 N Gef.: 64,93 4,61Calc .: C 65.08 H 4.44 N Gef .: 64.93 4.61
5-Methyl-6-[2-(2-thienyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H) pyridazinon5-Methyl-6- [2- (2-thienyl) -benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-4-(5-methyl-4,5-dihydro-3(2H) pyridazinon-6-yl)-phenyl]-thiophen-3-carbonsäureamid und Polyphosphorsäure bei 13O0C analog Beispiel 29. Ausbeute: 16,1 % der Theorie, Schmelzpunkt: 2220CPrepared from N- [2-hydroxy-4- (5-methyl-4,5-dihydro-3 (2H) -pyridazinone-6-yl) -phenyl] -thiophene-3-carboxylic acid amide and polyphosphoric acid at 13O 0 C analogously to Example 29 Yield: 16.1% of theory, melting point: 222 ° C.
Ber.: C 61,72 H 4,21 _ N 13,50 S 10,30Calc .: C 61.72 H 4.21 N 13.50 S 10.30
Gef.: 61,68 4,42 13,50 10,25Gef .: 61.68 4.42 13.50 10.25
5-Methyl-6-[2-(3-pyridyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H) pyridazinon5-Methyl-6- [2- (3-pyridyl) -benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-4-(5-methyl-4,5-dihydro-3(2Ή)-pyridazinon-6-yl)-phenyl]-pyridin-3-carbonsäureamid und Polyphosphorsäure bei 15O0C analog Beispiel 29. Ausbeute: 25 % der Theorie, Schmelzpunkt: 2180CPrepared from N- [2-hydroxy-4- (5-methyl-4,5-dihydro-3 (2Ή) -pyridazinone-6-yl) -phenyl] -pyridine-3-carboxamide and polyphosphoric acid at 15O 0 C analogously to Example 29. Yield: 25% of theory, melting point: 218 ° C.
Ber.: C 66,66 H 4,61 N 18,29 Gef.: 66,44 4,69 18,15Calc .: C 66.66 H 4.61 N 18.29 F .: 66.44 4.69 18.15
5-Methyl-'6- [2- (2-pyrazinyl) -benzoxazol-6-yl] -4, 5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (2-pyrazinyl) -benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hyd"roxy-4-(5-methyl-4, 5-dihydro-3 (2H) pyridazinon-6-yl).-phenyl]-pyrazin-2-carbonsäureamid und Polyphosphorsäure analog Beispiel Ausbeute: 21,7 % der Theorie, Schmelzpunkt: 242°C Ber.: C 62,53 H 4,26 N 22,79 Gef. : 62,80 4,17 22,60Prepared from N- [2-hydroxy-4- (5-methyl-4,5-dihydro-3 (2H) -pyridazinone-6-yl) -phenyl] -pyrazine-2-carboxamide and polyphosphoric acid analogously to Example Yield: 21.7% of theory, melting point: 242 ° C calc .: C 62.53 H 4,26 N 22,79 Gef.: 62,80 4,17 22,60
5-Methyl-6- [2-(4-pyridyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H) pyridazinon5-methyl-6- [2- (4-pyridyl) -benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-4-(5-methyl-4,5-dihydro-3(2H) pyridazinon-6-yl)-phenyl]-pyridin-4-carbonsäureamid und Polyphosphorsäure analog Beispiel 'Ausbeute: 49,1 % der Theorie, Schmelzpunkt: 2280C Ber.: C 66,66 H 4,61 N 18,29 Gef.: 66,75 4,54 18,14Prepared from N- [2-hydroxy-4- (5-methyl-4,5-dihydro-3 (2H) pyridazinone-6-yl) -phenyl] -pyridine-4-carboxylic acid amide and polyphosphoric acid analogously to Example 'Yield: 49, 1% of theory, melting point: 228 ° C. Calc .: C 66.66 H 4.61 N 18.29 V: 66.75 4.54 18.14
5-Methyl-6-[2-(1-acetyl-4-piperidino)-benzoxazol-6-yl] 4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (1-acetyl-4-piperidino) -benzoxazol-6-yl] 4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-4-(5-methyl-4,5-dihydro-3(2H)-Prepared from N- [2-hydroxy-4- (5-methyl-4,5-dihydro-3 (2H) -]
248248
pyridazinon-6-yl)-phenyl]-1-acety1-piperidin-4-carbonsäurearnid und Polyphosphorsaure analog Beispiel 29. Ausbeute: 60,3 % der Theorie, Schmelzpunkt: 1990Cpyridazinone-6-yl) -phenyl] -1-acety1-piperidine-4-carboxylic acid arid and polyphosphoric acid analogously to Example 29. Yield: 60.3% of theory, melting point: 199 ° C.
Ber.: C 64,39 H 6,26 N 15,81 Gef.: 64,60 6,20 16,06Calc .: C 64.39 H 6.26 N 15.81 F .: 64.60 6.20 16.06
5-Methyl-6-[2-(4-methyl-5-oxazolyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (4-methyl-5-oxazolyl) benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-4-(5-methyl-4,5-dihydro-3(2H) pyridazinon-6-yl)-phenyl]-4-methyl-oxazol-5-carbonsäureamid und Polyphosphorsaure bei 1400C analog Beispiel Ausbeute: 28,2 % der Theorie, Schmelzpunkt: 2170CPrepared from N- [2-hydroxy-4- (5-methyl-4,5-dihydro-3 (2H) -pyridazinone-6-yl) -phenyl] -4-methyl-oxazole-5-carboxylic acid amide and polyphosphoric acid at 140 0 C analogous to Example Yield: 28.2% of theory, melting point: 217 ° C.
Ber.: C 61,93 H 4,55 N 18,05 Gef.: 62,12 4,70 18,28Calc .: C 61.93 H 4.55 N 18.05 Found: 62.12 4.70 18.28
5-Methyl-6-[2-(5-pyrimidinyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (5-pyrimidinyl) benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-4-(5-methyl-4,5-dihydro-3(2H) pyridazinon-6-yl)-phenyl]-pyrimidin-5-carbonsäureamid und Polyphosphorsaure bei 1500C analog Beispiel 29.' Ausbeute: 16,3 % der Theorie, Schmelzpunkt: 2790CPrepared from N- [2-hydroxy-4- (5-methyl-4,5-dihydro-3 (2H) -pyridazinone-6-yl) -phenyl] -pyrimidine-5-carboxylic acid amide and polyphosphoric acid at 150 0 C in analogy to Example 29 . ' Yield: 16.3% of theory, melting point: 279 ° C.
Ber.: C 62,53 H 4,26 N 22,79 Gef.: 62,48 4,27 22,57Calc .: C 62.53 H 4.26 N 22.79 Found: 62.48 4.27 22.57
Λ 4 ο4 ο
5-Methyl-6- [2-(2-amino-5-pyridyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (2-amino-5-pyridyl) -benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-4-(5-methyl-4,5-dihydro-3(2H)-pyridazinon-6-yl) -phenyl] -ö-acetamino-pyridin^-carbonsäureamid und Polyphosphorsäure bei 1500C analog Beispiel 29. Ausbeute: 8,2 % der Theorie, Massenspektrum: M = 321 m/ePrepared from N- [2-hydroxy-4- (5-methyl-4,5-dihydro-3 (2H) -pyridazinone-6-yl) -phenyl] -o-acetamino-pyridine ^ -carboxamide and polyphosphoric acid at 150 0 C analogously to Example 29. Yield: 8.2% of theory, mass spectrum: M = 321 m / e
Ber.: C 63,54 H 4,71 N 21,79 Gef.: 63,45 4,85 21,59Calc .: C 63.54 H 4.71 N 21.79 F .: 63.45 4.85 21.59
6-[2-(2-pyridyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinon6- [2- (2-pyridyl) benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-4-(4,5-dihydro-3(2H)-pyridazinon-6-yl)-phenyl]-pyridin-2-carbonsäureamid und Polyphos· phorsäure analog Beispiel 29.Prepared from N- [2-hydroxy-4- (4,5-dihydro-3 (2H) -pyridazinone-6-yl) -phenyl] -pyridine-2-carboxamide and polyphosphoric acid analogously to Example 29.
Ausbeute: 29,1 % der Theorie,.Yield: 29.1% of theory.
Schmelzpunkt: 282-283°CMelting point: 282-283 ° C
Ber. : C 65,75 H- 4,14 N 19,17 Gef.: 66,03 4,16 19,33Ber. : C 65.75 H- 4,14 N 19,17 F .: 66,03 4,16 19,33
6-[2-(2-Furyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinon6- [2- (2-furyl) benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-4-(4,5-dihydro-3(2H)-pyrida-Prepared from N- [2-hydroxy-4- (4,5-dihydro-3 (2H) -pyrida-
zinon-6-yl)-phenyl]-furan-2-carbonsäurea'mid und Polyphos· phorsäure analog Beispiel 29. Ausbeute: 31,3 % der Theorie, Schmelzpunkt: 261-2620C Ber.: C 64,05 H 3,94 N 14,94 Gef.: 63,89 4,02 14,91Zinon-6-yl) -phenyl] -furan-2-carbonsäurea'mid and Polyphos · phoric acid analogously to Example 29. Yield: 31.3% of theory, Melting point: 261-262 0 C Calc .: C 64.05 H 3 , 94 N 14.94 F .: 63.89 4.02 14.91
5-Methyl-6- [2-(4-thiomorpholino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (4-thiomorpholino) -benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 5-Methyl-6-(2-methylthio-benzoxazol-6-yl)-4,5-dihydro-3(2H)-pyridazinon und Thiomorpholin analog Beispiel 18.Prepared from 5-methyl-6- (2-methylthio-benzoxazol-6-yl) -4,5-dihydro-3 (2H) -pyridazinone and thiomorpholine analogously to Example 18.
Ausbeute: 56,5 % der Theorie, Schmelzpunkt: 218°C Ber.: C 58,16 H 5,49 N 16,96 S 9,70 Gef.: 58,24 5,49 17,20 9,54Yield: 56.5% of theory, m.p .: 218 ° C. Calc .: C, 58.16, H, 5.49, N, 16.96, S, 9.70, Foth .: 58.24, 5.49, 17.20, 9.54
5-Methyl-6- [2-(1-piperidino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (1-piperidino) -benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 5-Methyl-6-(2-methylthio-benzoxazol-6-yl)-4,5-dihydro-3(2H)-pyridazinon und Piperidin analog Beispiel 18.Prepared from 5-methyl-6- (2-methylthio-benzoxazol-6-yl) -4,5-dihydro-3 (2H) -pyridazinone and piperidine analogously to Example 18.
Ausbeute: 85,4 % der Theorie, Schmelzpunkt: 235°CYield: 85.4% of theory, melting point: 235 ° C
Ber.: C 65,37 H 6,45 N 17,94Calc .: C 65.37 H 6.45 N 17.94
Gef. : 65,45 6,50 18,02Gef.: 65.45 6.50 18.02
.36- -4S 3.36- - 4 S 3
5-Methyl-6-[2-(l-oxido-4-thiomorpholino)-benzoxazol-6-yl] 4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (1-oxido-4-thiomorpholino) -benzoxazol-6-yl] 4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 5-Methyl-6-(2-methylthio-benzoxazol-6-yl)-4,5-dihydro-3(2H)-pyridazinon und 1-Oxido-thiomorpholin analog Beispiel 18Prepared from 5-methyl-6- (2-methylthio-benzoxazol-6-yl) -4,5-dihydro-3 (2H) -pyridazinone and 1-oxidothiomorpholine analogously to Example 18
Ausbeute: 65,3 % der Theorie, Schmelzpunkt: 257-26O0CYield: 65.3% of theory, melting point: 257-26O 0 C.
Ber.: C 55,48 H 5,24 N 16,17 S 9,26 O 13,86 Gef.: · 55,60 5,20 16,44 9,44 13,61Calc .: C 55.48 H 5.24 N 16.17 S 9.26 O 13.86 F .: 55.60 5.20 16.44 9.44 13.61
5-Methyl-6-[2-(l,l-dioxido-4-thiomorpholino)-benzoxazol-6-yl] 4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (1,1-dioxo-4-thiomorpholino) -benzoxazol-6-yl] 4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 5-Methyl-6-(2-methylthio-benzoxazol-6-yl)-4,5-dihydrö-3(2H)-pyridazinon und 1,1-Dioxido-thiomorpholin analog Beispiel 18.Prepared from 5-methyl-6- (2-methylthio-benzoxazol-6-yl) -4,5-dihydro-3 (2H) -pyridazinone and 1,1-dioxo-thiomorpholine analogously to Example 18.
Ausbeute: 63,5 % der Theorie,Yield: 63.5% of theory,
Schmelzpunkt: 2800CMelting point: 280 ° C.
Ber.: C 53,03 H 5,00 N 15,46 S 8,85 Gef.: 53,00 5,16 15,51 8,96Calc .: C 53.03 H 5.00 N 15.46 S 8.85 G .: 53.00 5.16 15.51 8.96
5-Methyl-6-[2-(4-methyl-l-piperazinyl)-benzoxazol-6-yl]-4,5· d'ihydro-3 (2H) -pyridazinon5-Methyl-6- [2- (4-methyl-1-piperazinyl) -benzoxazol-6-yl] -4,5x-di-ihydro-3 (2H) -pyridazinone
Hergestellt aus 5-Methyl-6-(2-methylthio-benzoxazol-6-yl) -Prepared from 5-methyl-6- (2-methylthio-benzoxazol-6-yl) -
4,5-dihydro-3(2H)-pyridazinon und N-Methyl-piperazin analog Beispiel 18.4,5-dihydro-3 (2H) -pyridazinone and N-methylpiperazine analogously to Example 18.
Ausbeute: 61 % der Theorie, Schmelzpunkt: 1980CYield: 61% of theory, melting point: 198 ° C.
Ber.: C 62,37 H 6,47 N 21,39 Gef.: 62,62 6,50 21,44Calc .: C 62.37 H 6.47 N 21.39 F .: 62.62 6.50 21.44
5-Methyl-6-[2-(4-carbäthoxy-l-piperazinyl)-benzoxazol-6-yl] 4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (4-carbethoxy-1-piperazinyl) -benzoxazol-6-yl] 4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 5-Methyl-6-(2-methylthio-benzoxazol-6-yl) 4,5-dihydro-3(2H)-pyridazinon und 4-Carbäthoxy-piperazin analog Beispiel 18.Prepared from 5-methyl-6- (2-methylthio-benzoxazol-6-yl) 4,5-dihydro-3 (2H) -pyridazinone and 4-carbethoxy-piperazine analogously to Example 18.
Ausbeute: 72,7 % der Theorie, Schmelzpunkt: 239°C Ber.: C 59,21 H 6,02 N 18,17 Gef.: 59,53 6,00 18,37Yield: 72.7% of theory, melting point: 239 ° C. Calc .: C 59.21 H 6.02 N 18.17. Found: 59.53 6.00 18.37
5-Methyl-6-[2-(1-pyrrolidinyl)-benzoxazol-6-yl]-4,5-dihydro· 3(2H)-pyridazinon5-methyl-6- [2- (1-pyrrolidinyl) -benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 5-Methyl-6-(2-methylthio-benzoxazol-6-yl)-4,5-dihydro-3(2H)-pyridazinon und Pyrrolidin analog BeispielPrepared from 5-methyl-6- (2-methylthio-benzoxazol-6-yl) -4,5-dihydro-3 (2H) -pyridazinone and pyrrolidine analogously to Example
18. ·18th ·
Ausbeute: 73,8 % der Theorie,Yield: 73.8% of theory,
Schmelzpunkt: 234°C Ber.:' C 64,41 H 6,08 N 18,78Melting point: 234 ° C. Calc .: C 64.41 H 6.08 N 18.78
Gef.: 64,64 6,07 18,85Gef .: 64.64 6.07 18.85
Beispiel 49Example 49
5-Methyl-6-[2-(1-piperazinyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (1-piperazinyl) benzoxazole-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 5-Methyl-6-(2-methylthio-benzoxazol-6-yl)-4,5-dihydro-3(2H)-pyridazinon und Piperazin in der Schmelze analog Beispiel 18Prepared from 5-methyl-6- (2-methylthio-benzoxazol-6-yl) -4,5-dihydro-3 (2H) -pyridazinone and piperazine in the melt analogously to Example 18
'Ausbeute: 70,0 % der Theorie, Schmelzpunkt: 2130C'Yield: 70.0% of theory, melting point: 213 0 C.
Ber.: C 61,33 H 6,11 N 22,35 Gef.: 61,56 6,01 22,51Calc .: C 61.33 H 6.11 N 22.35 F .: 61.56 6.01 22.51
5-Methyl-6-[2-(4-methyl-l-imidazolyl)-benzoxazol-6-yl]-4,5-dihydro-3 (2H)-pyridazinon5-Methyl-6- [2- (4-methyl-1-imidazolyl) -benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 5-Methyl-6-(2-methylthio-benzoxazol-6-yl)-4,5-dihydro-3(2H)-pyridazinon und 4-Methyl-imidazol bei 15O0C analog Beispiel 18.Prepared from 5-methyl-6- (2-methylthio-benzoxazol-6-yl) -4,5-dihydro-3 (2H) -pyridazinone and 4-methyl-imidazole at 15O 0 C analogously to Example 18.
Ausbeute: 73,5 % der Theorie, - -Yield: 73.5% of theory, - -
Schmelzpunkt: 258°CMelting point: 258 ° C
Ber.: C 62,13 H 4,89 N 22,64 Gef.: 62,05 4,86 22,50Calc .: C 62.13 H 4.89 N 22.64 F .: 62.05 4.86 22.50
6-[2-(1-Piperidino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinon6- [2- (1-piperidino) benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 6-(2-Methylthio-benzoxazol-6-yl)-4,5-dihy-Prepared from 6- (2-methylthio-benzoxazol-6-yl) -4,5-dihy
- 39 - ·Μ ν - Ö- 39 - · Μ ν - Ö
dro-3(2H)-pyridazinon und Piperidin analog Beispiel Ausbeute: 62 % der Theorie, Schmelzpunkt: 198-1990Cdro-3 (2H) -pyridazinone and piperidine analogously to Example Yield: 62% of theory, Melting point: 198-199 0 C.
Ber.: C 64,41 H 6,08 N 18,78 Gef.: 64,62 6,07 18,61Calc .: C, 64.41, H, 6.08, N, 18.78, Fn: 64.62, 6.0, 18.71
6-[2-(4-Morpholino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinon6- [2- (4-morpholino) benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 6-(2-Methylthio-benzoxazol-6-yl)-4,5-dihydro-3(2H)-pyridazinon und Morpholin analog Beispiel Ausbeute: 73,3 % der Theorie, Schmelzpunkt: 2400CPrepared from 6- (2-methylthio-benzoxazol-6-yl) -4,5-dihydro-3 (2H) -pyridazinone and morpholine analogously to Example Yield: 73.3% of theory, Melting point: 240 0 C.
Ber.: C 59,99 H 5,37 N 18,66 Gef.: 60,20 5,37 18,81Calc .: C 59.99 H 5.37 N 18.66 V .: 60.20 5.37 18.81
6- [2- (1-Pyrrolidinyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H) pyridazinon6- [2- (1-Pyrrolidinyl) -benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 6-(2-Methylthio-benzoxazol-6-yl)-4,5-dihydro-3(2H)-pyridazinon und Pyrrolidin analog Beispiel Ausbeute: 78,9 % der Theorie, Schmelzpunkt: 265-266°CPrepared from 6- (2-methylthio-benzoxazol-6-yl) -4,5-dihydro-3 (2H) -pyridazinone and pyrrolidine analogous to Example Yield: 78.9% of theory, m.p .: 265-266 ° C
Ber.: C 63,37 . H 5,67 N 19,71 Gef. : 63,50 ' 5,73 19,55Re: C 63.37. H 5.67 N 19.71 Vessel: 63.50 '5.73 19.55
- 40 - -2 43 - 40 - -2 43
Beispiel 54Example 54
6-[2-(4-Methyl-l-imidazolyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinon6- [2- (4-methyl-l-imidazolyl) benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 6-(2-Methylthio-benzoxazol-6-yl)-4,5-dihydro-3(2H)-pyridazinon und 4-Methyl-imidazol bei 1500C analog Beispiel 18. Ausbeute: 17 % der Theorie, Schmelzpunkt: 280-2820C Ber.: C 61,01 H 4,44 N 23,72 Gef. : 60,80 4,44 23,49Prepared from 6- (2-methylthio-benzoxazol-6-yl) -4,5-dihydro-3 (2H) -pyridazinone and 4-methyl-imidazol at 150 0 C analogously to Example 18. Yield: 17% of theory, m.p. : 280-282 0 C Calc .: C 61.01 H 4.44 N 23.72 Found:. 60.80 4.44 23.49
6-[2-(4-Carbäthoxy-l-piperazinyl)-benzoxazol-6-yl] -4, 5-dihydro-3(2H)-pyridazinon6- [2- (4-Carbethoxy-1-piperazinyl) -benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 6-( 2-Methylthio-benzoxazol-6-yl)-4,5-dihydro-3(2H)-pyridazinon und 4-Carbäthoxy-piperazin analog Beispiel 18. Ausbeute: 50,1 % der Theorie, Schmelzpunkt: 242-243°C Ber.: C 58,21 H 5,70 N 18,86 Gef.: 58,39 5,84 18,65Prepared from 6- (2-methylthio-benzoxazol-6-yl) -4,5-dihydro-3 (2H) -pyridazinone and 4-carbethoxy-piperazine analogously to Example 18. Yield: 50.1% of theory, m.p .: 242 -243 ° C calc .: C 58.21 H 5.70 N 18.86 F .: 58.39 5.84 18.65
6-[2-(1-Piperazinyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H) pyridazinon6- [2- (1-piperazinyl) -benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 6-(2-Methylthio-benzoxazol-6-yl)-4,5-dihy-Prepared from 6- (2-methylthio-benzoxazol-6-yl) -4,5-dihy
JL H 8 - 41 - JL H 8 - 41 -
dro-3(2H)-pyridazinon und Piperazin (Schmelze) analog Beispiel 18.dro-3 (2H) -pyridazinone and piperazine (melt) analogously to Example 18.
Ausbeute: 36,7 % der Theorie, Schmelzpunkt: 182-1830CYield: 36.7% of theory, melting point: 182-183 0 C.
Ber.: C 60,19 H 5,72 .N 23,40 Gef.: 60,20 5,60 23,43Calc .: C 60.19 H 5.72. N 23.40 Found: 60.20 5.60 23.43
6-[2-(l-Oxido-4-thiomorpholino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinon6- [2- (1-oxido-4-thiomorpholino) -benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 6-(2-Methylthio-benzoxazol-6-yl)-4,5-dihydro-3(2H)-pyridazinon und 1-Oxido-thiomorpholin analog Beispiel 18.Prepared from 6- (2-methylthio-benzoxazol-6-yl) -4,5-dihydro-3 (2H) -pyridazinone and 1-oxidothiomorpholine analogously to Example 18.
Ausbeute: 39,1 % der Theorie, Schmelzpunkt: > 3100CYield: 39.1% of theory, melting point:> 310 ° C.
Ber.: C 54,20 H 4,85 N 16,86 S 9,65 Gef.: 54,35 5,11 16,87 9,57Calc .: C 54.20 H 4.85 N 16.86 S 9.65 V .: 54.35 5.11 16.87 9.57
6-[2-(1,1-Dioxido-4-thiomorpholino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinon6- [2- (1,1-dioxido-4-thiomorpholino) benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 6-(2-Methylthio-benzoxazol-6-yl)-4,5-dihydro-3(2H)-pyridazinon und 1,1-Dioxido-thiomorpholin analog Beispiel 18.Prepared from 6- (2-methylthio-benzoxazol-6-yl) -4,5-dihydro-3 (2H) -pyridazinone and 1,1-dioxo-thiomorpholine analogously to Example 18.
Ausbeute: 33,3 % der Theorie, Schmelzpunkt: 298-299°CYield: 33.3% of theory, melting point: 298-299 ° C
Ber.: C 51,71 H 4,63 N 16,08 S 9,20 Gef.: 51,60 4,83 16,14 9,30Calc .: C 51.71 H 4.63 N 16.08 S 9.20 F .: 51.60 4.83 16.14 9.30
6-[2-(4-Methyl-l-piperazinyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinon6- [2- (4-methyl-l-piperazinyl) benzoxazole-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 6-(2-Methylthio-benzoxazol-6-yl)-4,5-dihydro-3(2H)-pyridazinon und N-Methyl-piperazin analog Beispiel 18.Prepared from 6- (2-methylthio-benzoxazol-6-yl) -4,5-dihydro-3 (2H) -pyridazinone and N-methylpiperazine analogously to Example 18.
Ausbeute: 41,5 % der Theorie, Schmelzpunkt: 247-2480CYield: 41.5% of theory, Melting point: 247-248 0 C.
Ber.: C 61,33 H 6,11 N 22,35 Gef.: 61,20 6,31 22,35Calc .: C 61.33 H 6.11 N 22.35 V: 61.20 6.31 22.35
6- [2-(4-Thiomorpholino)-benzoxazol-6-yl]-4,5-dihydro-3(2H) pyridazinon6- [2- (4-thiomorpholino) -benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 6-(2-Methylthio-benzoxazol-6-yl)-4,5-dihydro-3(2H)-pyridazinon und Thiomorpholin analog Beispiel 18. Ausbeute: 39,2 % der Theorie, Schmelzpunkt: 253-254°CPrepared from 6- (2-methylthio-benzoxazol-6-yl) -4,5-dihydro-3 (2H) -pyridazinone and thiomorpholine analogously to Example 18. Yield: 39.2% of theory, melting point: 253-254 ° C
Ber.: C 56,95 H 5,10 N 17,71 S 10,13 Gef.: 56,87 5,21 17,68 10,30Calc .: C 56.95 H 5.10 N 17.71 S 10.13 F .: 56.87 5.21 17.68 10.30
5-n-Propyl-6-[2-(1-imidazolyl)-benzoxazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-n-propyl-6- [2- (1-imidazolyl) benzoxazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 5-n-Propyl-6-(2-methylthio-benzoxazol-5-yl) 4,5-dihydro-3(2H)-pyridazinon und Imidazol analog Beispiel 18.Prepared from 5-n-propyl-6- (2-methylthio-benzoxazol-5-yl) 4,5-dihydro-3 (2H) -pyridazinone and imidazole analogously to Example 18.
- 43 - < 4 8 36 - 43 - < 4 8 36
Ausbeute: 30,3 % der Theorie, Schmelzpunkt: 190-1920CYield: 30.3% of theory, Melting point: 190-192 0 C.
Ber.: C 63,15 H 5,30 N 21,67 Gef.: 63,09 5,51 21,52Calc .: C 63.15 H 5.30 N 21.67 V .: 63.09 5.51 21.52
5-n-Propyl-6-[2-(1-piperazinyl)-benzoxazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-n-propyl-6- [2- (1-piperazinyl) benzoxazole-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt' aus 5-n-Propyl-6-(2-methylthio-benzoxazol-5-yl) 4,5-dihydro-3(2H)-pyridazinon und Piperazin analog Beispiel 18.Prepared from 5-n-propyl-6- (2-methylthio-benzoxazol-5-yl) 4,5-dihydro-3 (2H) -pyridazinone and piperazine analogously to Example 18.
Ausbeute: 65,2 % der Theorie, Schmelzpunkt: 162-164°CYield: 65.2% of theory, melting point: 162-164 ° C
Ber.: C 63,33 H 6,79 N 20,52Calc .: C 63.33 H 6.79 N 20.52
Gef.: 62,98 6,93 20,32F .: 62.98 6.93 20.32
5-Methyl-6-[2-(1-imidazolyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (1-imidazolyl) benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 5-Methyl-6-(2-methylthio-benzoxazol-6-yl) 4,5-dihydro-3(2H)-pyridazinon und Imidazol bei 1600C analog Beispiel 18.Prepared from 5-methyl-6- (2-methylthio-benzoxazol-6-yl) 4,5-dihydro-3 (2H) -pyridazinone and imidazole at 160 0 C in analogy to Example eighteenth
Ausbeute: 17 % der Theorie, Schmelzpunkt: 219°CYield: 17% of theory, melting point: 219 ° C
Ber.: C 61,01 H 4,44 N 23,78 O 10,84Calc .: C 61.01 H 4.44 N 23.78 O 10.84
Gef.: 61,00 4,51 23,63 10,76Gef .: 61.00 4.51 23.63 10.76
- 44 - 2 is 3- 44 - 2 is 3
5-Methyl-6-[2-(4-morpholino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (4-morpholino) benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 5~Methyl-6-(2-methylthio-benzoxazol-6-yl)-4,5-dihydro-3(2H)-pyridazinon und Morpholin analog Beispiel 18.Prepared from 5-methyl-6- (2-methylthio-benzoxazol-6-yl) -4,5-dihydro-3 (2H) -pyridazinone and morpholine analogously to Example 18.
Ausbeute: 81,2 % der Theorie, Schmelzpunkt: 2090CYield: 81.2% of theory, melting point: 209 ° C.
Ber.: C 61,14 H 5,77 N 17,82. Gef.: 60,93 5,59 17,91Calc .: C 61.14 H 5.77 N 17.82. Gef .: 60,93 5,59 17,91
6-[2-(3-Thienyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinon6- [2- (3-thienyl) benzoxazole-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-4-(4,5-dihydro-3(2H)-pyridazinon-6-yl)-phenyl]-thiophen-S-carbonsäureamid und Eisessig/p-Toluolsulfonsäure analog Beispiel 30.Prepared from N- [2-hydroxy-4- (4,5-dihydro-3 (2H) -pyridazinone-6-yl) -phenyl] -thiophene-S-carboxamide and glacial acetic acid / p-toluenesulfonic acid analogously to Example 30.
Ausbeute: 22,2 % der Theorie,Yield: 22.2% of theory,
Schmelzpunkt: 272-273°CMelting point: 272-273 ° C
Ber.: C 60,59 H 3,73 N 14,13 S 10,78 Gef.: 60,60 3,68 13,99 10,66Calc .: C 60.59 H 3.73 N 14.13 S 10.78 V .: 60.60 3.68 13.99 10.66
5-Methyl-6- [2-(2-acetamido-5-pyridyl)-benzoxazol-6-yl] 4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (2-acetamido-5-pyridyl) -benzoxazol-6-yl] 4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-4-(5-methyl-4,5-dihydro-3(2H) -Prepared from N- [2-hydroxy-4- (5-methyl-4,5-dihydro-3 (2H) -]
- 45 - ' 2 48 36- 45 - '2 48 36
pyridazinon-6-yl)-phenyl]^-aeetamino-pyridin-S-carbonsäurepyridazinon-6-yl) phenyl] ^ - aeetamino-pyridin-S-carboxylic acid
amid und Eisessig/p-Toluolsulfonsäure analog Beispiel 30. Ausbeute: 12 % der Theorie', Schmelzpunkt: > 3000Camide and glacial acetic acid / p-toluenesulfonic acid analogously to Example 30. Yield: 12% of theory, melting point:> 300 ° C.
Ber.: C 62,80 H 4,72 N 19,27Calc .: C 62.80 H 4.72 N 19.27
Gef. : 62,66 . 4,96 19,25Gef.: 62.66. 4,96 19,25
5-Methyl-6-[2-(2,6-dichlor-3-pyridyl)-benzoxazol-6-yl] 4,5-dihydro-3(2H)-pyridazinon5-methyl-6- [2- (2,6-dichloro-3-pyridyl) -benzoxazol-6-yl] 4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-4-(5-methyl-4,5-dihydro-3(2H) pyridazinon-6-yl)-phenyl]-2,6-dichlor-pyridin-3-carbonsäureamid und Eisessig/p-Toluolsulfonsäure analog Beispiel 30. Ausbeute: 40 % der Theorie, Schmelzpunkt: 268-2700CPrepared from N- [2-hydroxy-4- (5-methyl-4,5-dihydro-3 (2H) pyridazinone-6-yl) -phenyl] -2,6-dichloro-pyridine-3-carboxamide and glacial acetic acid. p-toluenesulfonic acid analogously to example 30. yield: 40% of theory, melting point: 268-270 0 C.
Ber.: C 54,42 H 3,22 N 14,93 Cl 18,90 Gef.: 54,52 3,33 14,70 18,88Calc .: C 54.42 H 3.22 N 14.93 Cl 18.90 F .: 54.52 3.33 14.70 18.88
5-n-Propyl-6-[2-(4-pyridyl)-benzoxazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-n-propyl-6- [2- (4-pyridyl) benzoxazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus N-[2-Hydroxy-5-(5-n-propyl-4,5-dihydro-3(2H)-pyridazinon-6-yl)-phenyl]-pyridin-4-carbonsäure- amid analog Beispiel 8.Prepared from N- [2-hydroxy-5- (5-n-propyl-4,5-dihydro-3 (2H) -pyridazinone-6-yl) -phenyl] -pyridine-4-carboxylic acid amide analogously to Example 8.
Ausbeute: 40,1 % der Theorie,Yield: 40.1% of theory,
Schmelzpunkt: 200-2020CMelting point: 200-202 0 C
Ber.: C 68,24 H 5,42 N 16,76Calc .: C 68.24 H 5.42 N 16.76
; Gef.: 68,26 5,38 16,91; Gef .: 68.26 5.38 16.91
- 46 - 2 48 3 6- 46 - 2 48 3 6
5-Methyl-6-[2-(2-chlor-6-morpholino-3-pyridyl)-benzoxäzol-6-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (2-chloro-6-morpholino-3-pyridyl) -benzoxäzol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 5-Methyl-6-[2-(2,6-dichlor-3-pyridyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinon und Morpholin analog Beispiel 28Prepared from 5-methyl-6- [2- (2,6-dichloro-3-pyridyl) -benzoxazol-6-yl] -4,5-dihydro-3 (2H) -pyridazinone and morpholine analogous to Example 28
Ausbeute: 22 % der Theorie, Schmelzpunkt: 236°C Yield: 22% of theory, melting point: 236 ° C
5-Methyl-6-[2-(1-imidazolyl)-benzimidazol-5-yl]-4,5-dihydro· 3(2H)-pyridazinon5-Methyl-6- [2- (1-imidazolyl) -benzimidazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
a) 4- (2-Chlor-benzirnidazol-5-yl) ^-oxo-S-methyl-buttersäuremethy !ester a) 4- (2-chloro-benzimidazol-5-yl) ^ -oxo-S-methyl-butyric acid methyl ester
12 g (46 itiMol) 4-(Benzimidazol-2-on-5-yl)-4-oxo-3-methylb\ittersäuremethylester werden in 200 ml Phosphoroxychlorid 1,5 Stunden lang unter Rückfluß erhitzt. Anschließend wird das überschüssige-Phosphoroxychlorid im Vakuum abdestilliert und der verbleibende Rückstand unter Eiskühlung mit Wasser zersetzt. Man neutralisiert mit Ammoniak, extrahiert mit Essigester, wäscht die Essigesterphase zweimal mit Wasser, trocknet sie über Magnesiumsulfat und engt zur Trockne ein. Der Rückstand wird durch Chromatographie gereinigt (Kieselgel: 0,032-0,063 mm, Elutionsmittel: Essigester/Petroläther = 2/1) .12 g (46 μl) of methyl 4- (benzimidazol-2-on-5-yl) -4-oxo-3-methylbate are refluxed in 200 ml of phosphorus oxychloride for 1.5 hours. Subsequently, the excess phosphorus oxychloride is distilled off in vacuo and the remaining residue is decomposed with ice cooling with water. It is neutralized with ammonia, extracted with ethyl acetate, the ethyl acetate phase is washed twice with water, dried over magnesium sulfate and concentrated to dryness. The residue is purified by chromatography (silica gel: 0.032-0.063 mm, eluant: ethyl acetate / petroleum ether = 2/1).
Ausbeute: 7,9 g (61,2 % der Theorie), Schmelzpunkt: 135-1360CYield: 7.9 g (61.2% of theory), Melting point: 135-136 0 C.
b) 4-[2-(1-ImidazoIyI)-benzimidazol-5-yl]-4-oxo-3-raethyl-b) 4- [2- (1-Imidazolyl) benzimidazol-5-yl] -4-oxo-3-ethyl
butt er säur eme thy !esterBut it is acid ester!
1,5 g (5,3 mMol) 4-(2-Chlor-benzimidazol-5-yl)-4-oxo-3-methyl-buttersäuremethylester und 1,1 g (16 mMol) Imidazol werden vermischt und 1,5 Stunden lang auf 13O0C erhitzt. Man erhält eine klare zähe Schmelze, die nach Abkühlen mit Wasser versetzt wird. Man extrahiert dreimal mit Essigester, wäscht die vereinigten Essigesterlösungen dreimal mit Wasser, trocknet sie über Magnesiumsulfat und dampft zur Trockne ein.1.5 g (5.3 mmol) of 4- (2-chloro-benzimidazol-5-yl) -4-oxo-3-methyl-butyric acid methyl ester and 1.1 g (16 mmol) of imidazole are mixed and left for 1.5 hours heated to 13O 0 C for a long time. This gives a clear tough melt, which is added after cooling with water. It is extracted three times with ethyl acetate, the combined ethyl acetate solutions are washed three times with water, dried over magnesium sulfate and evaporated to dryness.
Ausbeute: 1,5 g (90 % der Theorie), Schmelzpunkt: 130-1400CYield: 1.5 g (90% of theory), Melting point: 130-140 0 C.
•Ber.: C 61,53 H 5,16 ' N 17,94 Gef.: 61,21 5,47 17,87• Re: C 61.53 H 5.16 'N 17.94 F: 61.21 5.47 17.87
c) 5-Methyl-6-[2-(1-imidazolyl)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon c) 5-Methyl-6- [2- (1-imidazolyl) -benzimidazol-5-yl] -4,5- dihydro-3 (2H) -pyridazinone
1,4 g (4,3 mMol) 4-[2-(1-Imidazolyl)-benzimidazol-5-yl]-4-oxo-3-methyl-buttersäuremethylester werden mit 30 ml Essigsäure*und 3,8 ml 80%igem Hydrazinhydrat 1,25 Stunden lang auf 1050C erhitzt. Nach Abkühlen wird mit ca. 100 ml Wasser versetzt und dreimal mit Essigester extrahiert. Die vereinigten Essigesterlösungen werden zweimal mit Wasser gewaschen, über Magnesiumsulfat getrocknet und eingedampft. Der Rückstand wird chromatographisch gereinigt (Kieselgel:1.4 g (4.3 mmol) of methyl 4- [2- (1-imidazolyl) benzimidazol-5-yl] -4-oxo-3-methylbutyrate are mixed with 30 ml of acetic acid * and 3.8 ml of 80% Hydrazine hydrate heated to 105 0 C for 1.25 hours. After cooling, it is mixed with about 100 ml of water and extracted three times with ethyl acetate. The combined ethyl acetate solutions are washed twice with water, dried over magnesium sulfate and evaporated. The residue is purified by chromatography (silica gel:
0,032 - 0,063 mm, Elutionsmittel: Methylenchlorid/Ethanol = 1:0 bis 1:0,14).0.032-0.063 mm, eluent: methylene chloride / ethanol = 1: 0 to 1: 0.14).
Ausbeute: 0,29 g (22,9 % der Theorie), Schmelzpunkt: 282-2850C (Zers.)Yield: 0.29 g (22.9% of theory), Melting point: 282-285 0 C (dec.)
- 48 " Λ JJ ^ λ J Λ- 48 "Λ JJ ^ λ J Λ
5-Methyl-6- [2-(4-methyl-l-piperazinyl)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (4-methyl-1-piperazinyl) -benzimidazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 4-[2-(4-Methyl-l-piperazinyl)-benzimidazol-5-yl] -4-oxo-3-methyl-buttersäuremethylester und Hydrazinhydrat analog Beispiel 70cPrepared from methyl 4- [2- (4-methyl-1-piperazinyl) benzimidazol-5-yl] -4-oxo-3-methylbutyrate and hydrazine hydrate analogously to Example 70c
Ausbeute: 67 % der Theorie, Schmelzpunkt: 317-32O0C (Zers.).Yield: 67% of theory, melting point: 317-32O 0 C (dec.).
5-Methyl-6-[2-(4-morpholino)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (4-morpholino) -benzimidazole-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 4-[2-(4-Morpholino)-benzimidazol-5-yl]-4-oxo-3-methyl-buttersäuremethylester und Hydrazinhydrat analog Beispiel 70cPrepared from 4- [2- (4-morpholino) -benzimidazol-5-yl] -4-oxo-3-methyl-butyric acid methyl ester and hydrazine hydrate analogous to Example 70c
Ausbeute: 51 % der Theorie, Massenspektrum: M = 313 m/e IR-Spektrum (Methylenchlorid) : 1665 cm"-1· (Carbonyl)Yield: 51% of theory, mass spectrum: M = 313 m / e IR spectrum (methylene chloride): 1665 cm -1 "(carbonyl)
5-Methyl-6-[2-(1-pyrrolidinyl)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (1-pyrrolidinyl) -benzimidazole-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 4-[2-(1-Pyrrolidinyl)-benzimidazol-5-yl] 4-oxo-3-methyl-buttersäuremethylester und Hydrazinhydrat analog Beispiel 70c.Prepared from 4- [2- (1-pyrrolidinyl) benzimidazol-5-yl] 4-oxo-3-methyl-butyric acid methyl ester and hydrazine hydrate analogous to Example 70c.
C 4 S 3 <SC 4 S 3 <S
Ausbeute: 75,3 % der Theorie, Schmelzpunkt: 233-236°CYield: 75.3% of theory, m.p .: 233-236 ° C
Ber. : C 64,63 H 6,44 N 23,55 Gef.: 64,42 6,67 23,36Ber. : C 64.63 H 6.44 N 23.55 V: 64.42 6.67 23.36
5-Methyl-6-[2-(4-thiomorpholino)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridäzinon5-Methyl-6- [2- (4-thiomorpholino) -benzimidazole-5-yl] -4,5-dihydro-3 (2H) -pyridäzinon
Hergestellt aus 4-[2-(4-Thiomorpholino)-benzimidazol-5-yl] 4-oxo-3-methyl-buttersäuremethylester und Hydrazinhydrat analog Beispiel 70c.Prepared from 4- [2- (4-thiomorpholino) -benzimidazol-5-yl] 4-oxo-3-methyl-butyric acid methyl ester and hydrazine hydrate analogous to Example 70c.
Ausbeute: 73 % der Theorie,Yield: 73% of theory,
UV-Spektrum (Ethanol): 224 nm (0,18), 246 nm (0,28),UV spectrum (ethanol): 224 nm (0.18), 246 nm (0.28),
323 nm (0,33),323 nm (0.33),
IR-Spektrum (Methylenchlorid): 1665 cm" (Carbonyl) 1625-1630 cm"1 (C=N)IR spectrum (methylene chloride): 1665 cm "(carbonyl) 1625-1630 cm" 1 (C = N)
5-Methyl-6-[2-(2-pyrrolyl)-benzimidazol-5-yl]-4,5-dihydro· 3(2H)-pyridäzinon5-Methyl-6- [2- (2-pyrrolyl) -benzimidazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 4-[2-(2-Pyrrolyl)-benzimidazol-5-yl]-4-oxo-3-methyl-buttersäuremethylester und Hydrazinhydrat analog Beispiel 70c.Prepared from 4- [2- (2-pyrrolyl) -benzimidazol-5-yl] -4-oxo-3-methyl-butyric acid methyl ester and hydrazine hydrate analogous to Example 70c.
Ausbeute: 36 % der Theorie, Schmelzpunkt: 305-3100C (Zers.) IR-Spektrum (Methylenchlorid): 1630 cm" (Carbonyl)Yield: 36% of theory, Melting point: 305-310 0 C (dec.) IR spectrum (methylene chloride): 1630 cm '(carbonyl)
- so -' 2i8 3 6- so - 2i8 3 6
5-Methyl-6-[2-(l-oxido-4-thiomorpholino)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (l-oxido-4-thiomorpholino) -benzimidazole-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 4-[2-(l-Oxido-4-thiomorpholino)-benzimidazol-5-yl] -4-oxo-3-IIlethyl-buttersäuremethylester und Hydrazinhydrat analog Beispiel 70cPrepared from 4- [2- (l-oxido-4-thiomorpholino) benzimidazol-5-yl] -4-oxo-3-IIlethyl-butyric acid methyl ester and hydrazine hydrate analogous to Example 70c
Ausbeute: 84 % der Theorie, Schmelzpunkt: 1050C (Zers.)Yield: 84% of theory, Melting point: 105 0 C (dec.)
UV-Spektrum (Ethanol): 221 nm (0,34), 245 nm (0,53), 319 nm (0,63), IR-Spektrum (Methylenchlorid): 1655 cm (Carbonyl)UV spectrum (ethanol): 221 nm (0.34), 245 nm (0.53), 319 nm (0.63), IR spectrum (methylene chloride): 1655 cm (carbonyl)
5-Methyl-6-[2-(1-hexahydroazepinyl)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (1-hexahydroazepinyl) -benzimidazole-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 4-[2-(1-Hexahydroazepinyl)-benzimidazol-5-yl] -4-oxo-3-methyl-buttersäuremethylester und Hydrazinhydrat analog Beispiel 70cPrepared from 4- [2- (1-hexahydroazepinyl) benzimidazol-5-yl] -4-oxo-3-methyl-butyric acid methyl ester and hydrazine hydrate analogous to Example 70c
Ausbeute: 19 % der Theorie, Schmelzpunkt: 295-298°C (Zers.) Yield: 19% of theory, m.p .: 295-298 ° C (dec.)
Massenspektrum: M : 325 m/eMass spectrum: M: 325 m / e
5-Methyl-6-[2-(1-pyrazolyl)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (1-pyrazolyl) -benzimidazole-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 4-[2-(1-Pyrazolyl)-benzimidazol-5-yl]-4-oxo-Prepared from 4- [2- (1-pyrazolyl) -benzimidazol-5-yl] -4-oxo
3-methyl-buttersäuremethylester und Hydrazinhydrat analog Beispiel 70c.Methyl 3-methylbutyrate and hydrazine hydrate analogously to Example 70c.
Ausbeute: 37 % der Theorie, Schmelzpunkt: 290-2920CYield: 37% of theory, Melting point: 290-292 0 C.
5.Ber.: C 61,21 H 4,80 N 28,56 Gef.: 61,17 4,89 28,495.Ber .: C 61.21 H 4.80 N 28.56 Gef .: 61.17 4.89 28.49
5-Methyl-6-[2-(4-acetyl-l-piperazinyl)-benzimidazol-5-yl] 4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (4-acetyl-1-piperazinyl) -benzimidazol-5-yl] 4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 4-[2-(4-Acetyl-l-piperazinyl)-benzimidazol-5-yl] -4-oxo-3-methyl-buttersäuremethylester und Hydrazinhydrat analog Beispiel 70cPrepared from 4- [2- (4-acetyl-1-piperazinyl) benzimidazol-5-yl] -4-oxo-3-methyl-butyric acid methyl ester and hydrazine hydrate analogously to Example 70c
Ausbeute: 44 % der Theorie, Schmelzpunkt: 295-3020CYield: 44% of theory, melting point: 295-302 0 C.
Ber.: C 61,00 H 6,26 N 23,71 Gef.: 61,30 6,43 23,56Calc .: C 61.00 H 6.26 N 23.71 V .: 61.30 6.43 23.56
5-Methyl-6-[2-(imidazolidin-2-on-l-yl)-benzimidazol-5-yl] 4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (imidazolidin-2-one-1-yl) -benzimidazol-5-yl] 4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 4-[2-(Imidazolidin-2-on-l-yl)-benzimidazol-5-yl] -4-oxo-3-methyl-buttersäuremethylester und Hydrazinhydrat analog Beispiel 70cPrepared from 4- [2- (imidazolidin-2-one-l-yl) benzimidazol-5-yl] -4-oxo-3-methyl-butyric acid methyl ester and hydrazine hydrate analogous to Example 70c
Ausbeute: 7 % der Theorie, Schmelzpunkt: 285°C (Zers.) Yield: 7% of theory, melting point: 285 ° C. (dec.)
Massenspektrum: M = 312 m/eMass spectrum: M = 312 m / e
5-Methyl-6-[2-(1-piperidino)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (1-piperidino) -benzimidazole-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 4- [2-(1-Piperidino)-benzimidazol-5-yl]-4-oxo-3-rnethyl-buttersäuremethylester und Hydrazinhydrat' analog Beispiel 70cPrepared from 4- [2- (1-piperidino) benzimidazol-5-yl] -4-oxo-3-methyl-butyric acid methyl ester and hydrazine hydrate 'analogous to Example 70c
Ausbeute: 49 % der Theorie, Schmelzpunkt: 185°C (Zers.) 'Massenspekturm: M = 311 m/e Yield: 49% of theory, m.p .: 185 ° C (dec.) 'Mass: m = 311 m / e
Ί0 Beispiel 82 Ί0 Example 82
5-Methyl-6-[2-(3-hydroxy-4-methyl-2-pyrazolyl)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (3-hydroxy-4-methyl-2-pyrazolyl) -benzimidazole-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 4-[2-(3-Hydroxy-4-methyl-2-pyrazolyl)-benzimidazol-5-yl]-4-oxo-3-methyl-buttersäuremethylester und Hydrazinhydrat analog Beispiel 70c. · Ausbeute: 67 % der Theorie, Schmelzpunkt: 260-2650C (Zers.) Massenspekturm: M = 324 m/ePrepared from 4- [2- (3-hydroxy-4-methyl-2-pyrazolyl) -benzimidazol-5-yl] -4-oxo-3-methyl-butyric acid methyl ester and hydrazine hydrate analogous to Example 70c. · Yield: 67% of theory, Melting point: 260-265 0 C (dec.) Mass Spec tower: M = 324 m / e
5-Methyl-6-[2-(4-morpholino)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (4-morpholino) -benzimidazole-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
a) 4- [2-(4-Morpholino)-benzimidazol-5-yl]-4-oxo-3-methylbuttersäuremorpholid a) 4- [2- (4-Morpholino) -benzimidazol-5-yl] -4-oxo-3-methyl- butyric acid morpholide
Hergestellt aus 4-(2-Sulfo-benzimidazol-5-yl)-4-oxo-3-methyl-Prepared from 4- (2-sulfo-benzimidazol-5-yl) -4-oxo-3-methyl
24a 362 24a 362
buttersäure analog Beispiel 70abutyric acid analogously to Example 70a
Ausbeute: 30 % der Theorie, Massenspekturm: M = 386 m/e Yield: 30% of theory, mass M: M = 386 m / e
Ber.: C 62,16 H 6,78 N 14,50 Gef.: 61,90 6,86 14,36Calc .: C 62.16 H 6.78 N 14.50 F .: 61.90 6.86 14.36
b) 5-Methyl-6-[2-(4-morpholino)-benzimidazol-Sryl]-4,5-dihydro-3(2H)-pyridazinon b) 5-Methyl-6- [2- (4-morpholino) -benzimidazole-Sryl] -4,5-dihydro -3 (2H) -pyridazinone
Hergestellt aus 4-[2-(4-Morpholino)-benzimidazol-5-yl]-4-oxo-3-methyl-buttersäuremorpholid und Hydrazirihydrat' analog Beispiel 70c.Prepared from 4- [2- (4-morpholino) -benzimidazol-5-yl] -4-oxo-3-methyl-butyric acid morpholide and hydrazine hydrate analogous to Example 70c.
Ausbeute: 61 % der Theorie, Massenspektrum: M = 313 m/eYield: 61% of theory, mass spectrum: M = 313 m / e
5-Methy1-6-[2-(1-[I.2.4]triazolyl)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methy1-6- [2- (1- [I.2.4] triazolyl) -benzimidazole-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
a) 4-[l-[1.2.4]Triazolyl-benzimidazol-5-yl]-4-oxo-3-methy1-butter säur eine thy !ester a) 4- [l- [1.2.4] triazolyl-benzimidazol-5-yl] -4-oxo-3-methyl-1-ylic acid a thy! ester
260 mg (1 mMol) 4-(2-Chlor-benzimidazol-5-yl)-4-oxo-3-methyl-buttersäuremethylester werden mit 980 mg (14 mMol) 1,2,4-Triazol im Ölbad auf 1600C erhitzt. Nach 45 Minuten wird abgekühlt und mit 50 ml heißem Methanol verrieben. Anschliessenddestilliert man 10 bis 20 ml Methanol ab, saugt den erhaltenen Niederschlag noch warm ab und trocknet ihn an der Luft.260 mg (1 mmol) of 4- (2-chloro-benzimidazol-5-yl) -4-oxo-3-methyl-butyric acid methyl ester with 980 mg (14 mmol) of 1,2,4-triazole in an oil bath at 160 0 C. heated. After 45 minutes, cooled and triturated with 50 ml of hot methanol. Then distilled from 10 to 20 ml of methanol, the resulting precipitate is filtered while hot and dried in air.
Ausbeute: 0,22 g (74 % der Theorie), Schmelzpunkt: 300-3060C (Zers.).Yield: 0.22 g (74% of theory), Melting point: 300-306 0 C (dec.).
2 4g352 4g35
b) 5-Methyl-6-[2-(l-[1.2.4]triazolyl)-benzimidazol-5-yl]-4,5-dihydro-3 (2H) -pyridazinon b) 5-Methyl-6- [2- (1- [1,2,4] triazolyl) -benzimidazol-5-yl] -4,5- dihydro-3 (2H) -pyridazinone
280 mg (1 mMol) 4-[1-[1.2.4]Triazolyl-benzimidazol-5-yl]-A-oxo-3-methyl-buttersäuremethylester werden mit 5 ml Äthanol und 1 ml 98%igem Hydrazinhydrat eine Stunde lang auf 1000C erhitzt. Anschließend destilliert man das Lösungsmittel im Vakuum ab, versetzt den Rückstand mit Wasser und extrahiert 3 mal mit Essigester. Die vereinigten Essigesterphasen werden 2 mal mit Wasser gewaschen, über Natriumsulfat getrocknet und im Vakuum eingeengt. Der erhaltene Rückstand wird chromatographisch gereinigt (.Kieselgel, Elutionsmittel: Essigester).280 mg (1 mmol) of 4- [1- [1.2.4] triazolyl-benzimidazol-5-yl] -A- oxo-3-methyl-butyric acid methyl ester with 5 ml of ethanol and 1 ml of 98% hydrazine hydrate for one hour on 100 0 C heated. The solvent is then distilled off in vacuo, the residue is combined with water and extracted 3 times with ethyl acetate. The combined ethyl acetate phases are washed twice with water, dried over sodium sulfate and concentrated in vacuo. The residue obtained is purified by chromatography (.Kieselgel, eluent: ethyl acetate).
Ausbeute: 107 mg (40 % der Theorie), Schmelzpunkt: 228-2300C.Yield: 107 mg (40% of theory), Melting point: 228-230 0 C.
5-Methyl-6- [2-(3-methyl-l-pyrazolyl)-benzimidazoi-5-yl] -4, 5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (3-methyl-1-pyrazolyl) -benzimidazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
Hergestellt aus 5-Methyl-6-(2-chlor-benzimidazol-5-yl)-4,5-dihydro-3(2H)-pyridazinon' und 3-Methyl-pyrazol analog Beispiel 84b.Prepared from 5-methyl-6- (2-chloro-benzimidazol-5-yl) -4,5-dihydro-3 (2H) -pyridazinone 'and 3-methyl-pyrazole analogously to Example 84b.
Ausbeute: 87 % der Theorie,Yield: 87% of theory,
Schmelzpunkt: 320-3220C (Zers.)Melting point: 320-322 0 C (dec.)
Ber.: C 62,32 H 5,23 N 27,26Calc .: C 62.32 H 5.23 N 27.26
Gef.: 62,32 5,21 27,43F .: 62.32 5.21 27.43
5-Methyl-6-[2- (1-pyrrolidinyl)-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinon5-Methyl-6- [2- (1-pyrrolidinyl) -benzimidazol-5-yl] -4,5-dihydro-3 (2H) -pyridazinone
295 mg (1 mMol) 5-Methyl-6-[2-(1-pyrrolidinyl)-benzimidazol-5-yl]-3(2H)-pyridazinon werden in 20 ml Eisessig gelost und bei Raumtemperatur und 5 bar Wasserstoff in Gegenwart von Platindioxid hydriert. Nach Beendigung der Wasserstoffaufnahme wird vom Katalysator abfiltriert und das Filtrat im Vakuum zur Trockne eingeengt. Der Rückstand wird durch Chromatographie gereinigt (Kieselgel, Elutionsmittel: Methylenchlorid/Ethanol = 1:0 bis 1:0,2)295 mg (1 mmol) of 5-methyl-6- [2- (1-pyrrolidinyl) benzimidazol-5-yl] -3 (2H) -pyridazinone are dissolved in 20 ml of glacial acetic acid and at room temperature and 5 bar of hydrogen in the presence of Hydrogenated platinum dioxide. After completion of the hydrogen uptake, the catalyst is filtered off and the filtrate is concentrated to dryness in vacuo. The residue is purified by chromatography (silica gel, eluent: methylene chloride / ethanol = 1: 0 to 1: 0.2).
Ausbeute: 30 % der Theorie, Schmelzpunkt: 233-236°C Yield: 30% of theory, melting point: 233-236 ° C
Claims (6)
R,the general formula
R
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19853511110 DE3511110A1 (en) | 1985-03-27 | 1985-03-27 | NEW PYRIDAZINONE, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD248362A5 true DD248362A5 (en) | 1987-08-05 |
Family
ID=6266489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD86288285A DD248362A5 (en) | 1985-03-27 | 1986-03-25 | PROCESS FOR THE PREPARATION OF NEW PYRIDAZINONE |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0196005B1 (en) |
| JP (1) | JPS61227582A (en) |
| KR (1) | KR860007253A (en) |
| AT (1) | ATE48841T1 (en) |
| AU (1) | AU5530386A (en) |
| CA (1) | CA1257588A (en) |
| DD (1) | DD248362A5 (en) |
| DE (2) | DE3511110A1 (en) |
| DK (1) | DK131886A (en) |
| ES (4) | ES8705882A1 (en) |
| FI (1) | FI861288A7 (en) |
| GR (1) | GR860801B (en) |
| HU (1) | HUT42085A (en) |
| IL (1) | IL78251A0 (en) |
| NO (1) | NO861266L (en) |
| NZ (1) | NZ215616A (en) |
| PT (1) | PT82272B (en) |
| ZA (1) | ZA862248B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0350990A1 (en) * | 1988-07-11 | 1990-01-17 | Akzo Nobel N.V. | Pyridazinone derivatives |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3505609A1 (en) * | 1985-02-19 | 1986-08-21 | Merck Patent Gmbh, 6100 Darmstadt | BENZIMIDAZOLYL PYRIDAZINONE |
| US4725686A (en) * | 1985-11-22 | 1988-02-16 | William H. Rorer, Inc. | Benzodiazinone-pyridazinone and hydroxy-pyrazolyl compounds, cardiotonic compositions including the same, and their uses |
| DE3611343A1 (en) * | 1986-04-04 | 1987-10-08 | Boehringer Mannheim Gmbh | HETEROCYCLICALLY SUBSTITUTED BENZIMIDAZOLES, METHOD FOR THEIR PRODUCTION, MEDICINAL PRODUCTS AND INTERMEDIATE PRODUCTS |
| DE3734083A1 (en) * | 1987-10-08 | 1989-04-20 | Heumann Pharma Gmbh & Co | BENZIMIDAZOLES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
| DE3735207A1 (en) * | 1987-10-17 | 1989-04-27 | Basf Ag | MEDIUM BASED ON PHENYLPYRIDAZINONE DERIVATIVES FOR GROWTH ALLOY AND FET REDUCTION IN ANIMALS |
| FR2643903A1 (en) * | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING SAME, SYNTHESIS INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES, AND DUODENIAL ULCERS |
| DE4237656A1 (en) * | 1992-06-13 | 1993-12-16 | Merck Patent Gmbh | benzimidazole derivatives |
| FR2806093B1 (en) * | 2000-03-08 | 2002-05-03 | Inst Francais Du Petrole | SELECTIVE HYDROGENATION PROCESS COMPRISING A PARTIAL SEPARATION OF HYDROGEN BY MEMBRANE UPSTREAM OF A REACTIVE COLUMN |
| CN101410385B (en) | 2006-03-28 | 2011-08-24 | 高点制药有限责任公司 | Benzothiazoles having histamine H3 receptor activity |
| JP5794297B2 (en) * | 2010-05-07 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pyridazinone as a GPR119 agonist |
| CA2834548C (en) | 2011-04-28 | 2021-06-01 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| EP2877444B1 (en) | 2012-07-27 | 2020-09-02 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| US9914717B2 (en) | 2012-12-20 | 2018-03-13 | The Broad Institute, Inc. | Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors |
| WO2018086703A1 (en) | 2016-11-11 | 2018-05-17 | Bayer Pharma Aktiengesellschaft | Dihydropyridazinones substituted with phenylureas |
| EP3737362B1 (en) | 2018-01-12 | 2025-10-15 | Kdac Therapeutics, Inc. | Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer |
| EP3746079A1 (en) | 2018-01-31 | 2020-12-09 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| WO2023003468A1 (en) | 2021-07-23 | 2023-01-26 | Rijksuniversiteit Groningen | Novel inhibitors of histone deacetylase (hdac), and methods, compositions and uses related thereto. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES8101067A1 (en) * | 1978-08-25 | 1980-12-01 | Thomae Gmbh Dr K | PROCEDURE FOR THE PREPARATION OF NEW BENZHIMIDAZOLES REPLACED IN POSITION 5 OR 6 WITH A PYRIDAZINONE RING |
| DE3129447A1 (en) * | 1981-07-25 | 1983-02-10 | Dr. Karl Thomae Gmbh, 7950 Biberach | "NEW BENZTRIAZOLES, THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS" |
| DE3505609A1 (en) * | 1985-02-19 | 1986-08-21 | Merck Patent Gmbh, 6100 Darmstadt | BENZIMIDAZOLYL PYRIDAZINONE |
-
1985
- 1985-03-27 DE DE19853511110 patent/DE3511110A1/en not_active Withdrawn
-
1986
- 1986-03-18 AT AT86103687T patent/ATE48841T1/en not_active IP Right Cessation
- 1986-03-18 EP EP86103687A patent/EP0196005B1/en not_active Expired
- 1986-03-18 DE DE8686103687T patent/DE3667664D1/en not_active Expired - Lifetime
- 1986-03-21 DK DK131886A patent/DK131886A/en not_active Application Discontinuation
- 1986-03-25 IL IL78251A patent/IL78251A0/en unknown
- 1986-03-25 DD DD86288285A patent/DD248362A5/en unknown
- 1986-03-25 CA CA000505012A patent/CA1257588A/en not_active Expired
- 1986-03-26 GR GR860801A patent/GR860801B/en unknown
- 1986-03-26 AU AU55303/86A patent/AU5530386A/en not_active Abandoned
- 1986-03-26 ZA ZA862248A patent/ZA862248B/en unknown
- 1986-03-26 PT PT82272A patent/PT82272B/en unknown
- 1986-03-26 NZ NZ215616A patent/NZ215616A/en unknown
- 1986-03-26 JP JP61068255A patent/JPS61227582A/en active Pending
- 1986-03-26 FI FI861288A patent/FI861288A7/en not_active IP Right Cessation
- 1986-03-26 NO NO861266A patent/NO861266L/en unknown
- 1986-03-26 HU HU861275A patent/HUT42085A/en unknown
- 1986-03-26 ES ES553463A patent/ES8705882A1/en not_active Expired
- 1986-03-26 KR KR1019860002262A patent/KR860007253A/en not_active Withdrawn
- 1986-11-21 ES ES557218A patent/ES8705883A1/en not_active Expired
- 1986-11-21 ES ES557220A patent/ES8705885A1/en not_active Expired
- 1986-11-21 ES ES557219A patent/ES8705884A1/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0350990A1 (en) * | 1988-07-11 | 1990-01-17 | Akzo Nobel N.V. | Pyridazinone derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| NZ215616A (en) | 1990-01-29 |
| ATE48841T1 (en) | 1990-01-15 |
| DK131886A (en) | 1986-09-28 |
| FI861288A7 (en) | 1986-09-28 |
| EP0196005B1 (en) | 1989-12-20 |
| FI861288A0 (en) | 1986-03-26 |
| ZA862248B (en) | 1987-11-25 |
| ES557219A0 (en) | 1987-05-16 |
| PT82272B (en) | 1988-01-06 |
| DK131886D0 (en) | 1986-03-21 |
| ES8705883A1 (en) | 1987-05-16 |
| CA1257588A (en) | 1989-07-18 |
| ES553463A0 (en) | 1987-05-16 |
| KR860007253A (en) | 1986-10-10 |
| DE3511110A1 (en) | 1986-10-02 |
| ES8705882A1 (en) | 1987-05-16 |
| IL78251A0 (en) | 1986-07-31 |
| DE3667664D1 (en) | 1990-01-25 |
| ES8705884A1 (en) | 1987-05-16 |
| ES8705885A1 (en) | 1987-05-16 |
| ES557218A0 (en) | 1987-05-16 |
| NO861266L (en) | 1986-09-29 |
| HUT42085A (en) | 1987-06-29 |
| GR860801B (en) | 1986-07-21 |
| PT82272A (en) | 1986-04-01 |
| EP0196005A1 (en) | 1986-10-01 |
| JPS61227582A (en) | 1986-10-09 |
| AU5530386A (en) | 1986-10-02 |
| ES557220A0 (en) | 1987-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DD248362A5 (en) | PROCESS FOR THE PREPARATION OF NEW PYRIDAZINONE | |
| DE69013601T2 (en) | Heteroaryl piperazines as an antipsychotic agent. | |
| DE60203263T2 (en) | PYRAZOL DERIVATIVES AGAINST TGF OVEREXPRIMATION | |
| EP0877744B1 (en) | Substituted aza- and diazacycloheptane and cyclooctane compounds and their use | |
| DD258229A5 (en) | PROCESS FOR THE PREPARATION OF NEW HETEROCYCLICALLY SUBSTITUTED INDOOR DERIVATIVES | |
| EP1363904A1 (en) | Pyrazoles as tgf inhibitors | |
| EP0263352A1 (en) | Imidazo-benzoxazinones, their preparation and medicaments containing these compounds | |
| DE69713255T2 (en) | Pharmaceutical pyridine derivatives, their manufacturing processes and intermediates therefor | |
| EP0193013A2 (en) | Benzimidazolyl-pyridazinones | |
| AU640302B2 (en) | Pyridine compounds | |
| CH638202A5 (en) | 3- (PYRAZOL-1-YL) -PYRIDAZINE DERIVATIVES, THE SALTS THEREOF AND METHOD FOR THE PRODUCTION THEREOF. | |
| DE2845220A1 (en) | 6-Indolyl or quinolyl substd. pyridazinone derivs. - useful as antithrombotic and antihypertensive agents | |
| NZ207914A (en) | Indeno-pyridazinones and pharmaceutical compositions | |
| WO2004055024A1 (en) | 3-substituted 3,4-dihydro-thieno[2,3-d]pyrimidine-4-one-derivatives, production and use thereof | |
| WO1996002505A1 (en) | Thiopyridyl compounds for controlling helicobacter bacteria | |
| US4584297A (en) | Pyrrolo[1,2-c]-1,3-thiazines | |
| EP0128502B1 (en) | Substituted 6-(thien-2-yl)-3(2h)-pyridazinones and processes for their preparation | |
| NO841439L (en) | PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE TRIAZIN DERIVATIVES | |
| EP0175187A1 (en) | 3,4-Dihydro-2(1H)-pyridones and 2(1H)-pyridones containing imidazole groups, method for their preparation and medicaments containing them | |
| US3250769A (en) | 4:6-dialkyl-pyrazolo [3:4-b] pyridines | |
| Archibald et al. | Benzamidopiperidines. 2. Heterocyclic compounds related to indoramin | |
| US5684006A (en) | Isoxazole and pyrazole derivatives as dopamine receptor subtype ligands | |
| DE68913167T2 (en) | Indole derivatives, process for their preparation and pharmaceutical preparations containing them. | |
| EP0255704A2 (en) | Pyridazinone derivatives, process for their preparation and their use as medicines | |
| CS235976B2 (en) | Method of pyrimidine derivatives production |